Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | CYTOXAN | — | 1987-04-29 | fda.gov ↗ |
| Approved | US (FDA) | CYTOXAN (LYOPHILIZED) | — | 1959-11-16 | fda.gov ↗ |
Trials 1,733 · started per year
Also used as a comparator or background therapy in 2,728 trials
Press releases naming this drug 13 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-02-18 | Takeda | Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) takeda.com ↗ |
| 2021-10-27 | Takeda | Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors takeda.com ↗ |
| 2021-08-05 | Kite, A Gilead Company | Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer kitepharma.com ↗ |
| 2021-08-05 | Gilead Sciences | Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer gilead.com ↗ |
| 2021-06-17 | Kite, A Gilead Company | Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies kitepharma.com ↗ |
| 2021-06-17 | Gilead Sciences | Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies gilead.com ↗ |
| 2020-03-31 | Takeda | Takeda Receives Positive CHMP Opinion for ADCETRIS ® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide, Doxorubicin and Prednisone) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma takeda.com ↗ |
| 2020-03-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka's Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma otsuka.co.jp ↗ |
| 2018-12-04 | AbbVie | IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018 abbvie.com ↗ |
| 2018-04-03 | Pfizer | Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio pfizer.com ↗ |
| 2017-03-14 | Gilead Sciences | Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy gilead.com ↗ |
| 2016-07-25 | Gilead Sciences | Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies gilead.com ↗ |
| 2012-09-14 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Kyowa Hakko Kirin Returns to Otsuka Pharmaceutical the Rights to Develop and Market Busulfex, for Use As a Part of Conditioning Regimen Prior to Hematopoietic Progenitor Cell Transplantation, in Japan and in Asian Countries & Regions® otsuka.co.jp ↗ |
Evidence & citations 67 cited values
Every value below carries the sentence it was read from. 4,478 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cyclophosphamide | “Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane...” NCT05415215 ↗4386“Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone,...” NCT00577096 ↗ “The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating...” NCT02641314 ↗ “Patients initially received one 21-day cycle of standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP; rituximab 375 mg/m2, cyclophosphamide...” PMID 30948276 ↗ Apr 2019 “All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone)...” NCT05874778 ↗ “One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine,...” NCT06861244 ↗ “Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8,...” NCT06211452 ↗ “RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4),...” NCT03412266 ↗ “A Phase 3 Open Label Multicenter, Randomized Study to Compare the Efficacy and Safety of the Zevalin (Ibritumomab Tiuxetan) Therapeutic Regimen Following Cyclophosphamide,...” NCT00384111 ↗ “50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to...” NCT03295058 ↗ “The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1...” NCT04842318 ↗ “Recently, a less toxic regimen comprising reduced cyclophosphamide (Cy), fludarabine, and anti-thymocyte globulin (ATG) (Cy-Flu-ATG) was used to condition high-risk patients...” PMID 22526363 ↗ Apr 2012 “Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive...” NCT02885610 ↗ “CHOP is a first-generation, combination-chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone that has cured approximately 30 percent of...” PMID 7680764 ↗ Apr 1993 “standard CHOP chemotherapy (cyclophosphamide, 750mg per square meter of body-surface area,d1, vincristine, 1.4mg per square meter of body-surface area, maximal dose is 2mg d1,...” NCT02487316 ↗ “Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10\^9 to...” NCT01118091 ↗ “This study evaluates the addition of Acalabrutinib to current standard therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients...” NCT04546620 ↗ “The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1),...” NCT01279902 ↗ “The purpose of this study is to find out what the response is and the side effects are with chemotherapy using a combination of drugs called D.T. PACE (Dexamethasone,...” NCT00107614 ↗ “The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and...” NCT01393756 ↗ “Thirty-three newly diagnosed, symptomatic patients with MM received bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8 and 11, cyclophosphamide 300 mg/m(2) orally on days 1,...” PMID 19225538 ↗ Feb 2009 “bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4...” NCT01118026 ↗ “All patients will receive 8 cycles of R-CHOEP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m²,...” NCT03399513 ↗ “Lymphodepletion chemotherapy consisting of Fludarabine 30 mg/m2 IV once daily x 4 doses; and Cyclophosphamide 500mg/m2 IV once daily x 2 doses (starting with the first dose of...” NCT05010564 ↗ “Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100...” NCT00830544 ↗ “Epirubicin (90 mg/m², intravenous infusion) combined with cyclophosphamide (600 mg/m², intravenous infusion, every 2 weeks or 3 weeks, determined by investigators) for 4...” NCT07410559 ↗ “Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with...” NCT03123718 ↗ “Cyclophosphamide starting at 0.75 gm/m2 IV (decreased to 0.5 gm/m\^2 for patients \> than 70 or with estimated Glomerular Filtration Rate (eGFR) \< 20 ml/min) to be titrated up...” NCT01275287 ↗ “To determine the toxicity profile and tolerability of alemtuzumab (Campath) when administered in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone...” NCT00161590 ↗ “Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan...” NCT02405364 ↗ “At 6 months after randomization, patients who receive add-on cyclophosphamide will switch to azathioprine as a maintenance therapy and those who receive corticosteroids alone...” NCT03468972 ↗ “CHOP will be given 60-120 minutes following SQ administration of Alemtuzumab as follows: cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine...” NCT00323323 ↗ “The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate,...” NCT03320642 ↗ “rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab...” NCT00581854 ↗ “Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600...” NCT05569811 ↗ “Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an...” NCT00145626 ↗ “a) Cyclophosphamide: 750 mg/m2 i.v. drip, administered on D1; b) Doxorubicin: 50 mg/m2 i.v. drip (or Epirubicin: 70mg/m2 i.v. drip), administered on D1; c) Vincristine: 1.4...” NCT06961500 ↗ “zanubrutinib combined with Pola-R-CHP regimen: zanubrutinib 160mg bid d1-d21/C1-C6; polatuzumab 1.8mg/kg d1/C1-C6; rituximab 375mg/㎡, iv, d1/C1-C6; cyclophosphamide 750mg/㎡,...” NCT07371923 ↗ “The chemotherapy included nab-paclitaxel (100 mg/m2) and carboplatin (area under the curve, 1.5) on days 1, 8, and 15 in 28-day cycles for the first 16 weeks followed by...” PMID 39671272 ↗ Feb 2025 “standard doses of R-CHOP21 chemotherapy (375 mg/m(2) intravenous rituximab, 750 mg/m(2) intravenous cyclophosphamide, 50 mg/m(2) intravenous doxorubicin, and 1·4 mg/m(2)...” PMID 24831981 ↗ May 2014 “four cycles of docetaxel and cyclophosphamide or four cycles of weekly paclitaxel Combined with Trastuzumab followed by standard endocrine therapy( aromatase inhibitors or...” NCT07213206 ↗ “The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own...” NCT03526185 ↗ “Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by...” NCT06671262 ↗ “The purpose of this study is to evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment...” NCT07709715 ↗ “Patients receive a preparative lymphodepleting chemotherapy of intravenous cyclophosphamide and fludarabine from day -5 until day -3 (or Bendamustine on day -3 and day -2),...” NCT07166549 ↗ “Eligible patients were randomly assigned (1:1) by an online randomisation system based on the minimisation method to receive metronomic oral cyclophosphamide 50 mg per day plus...” PMID 29433963 ↗ Feb 2018 “Eligible patients received intravenous rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 (maximum 2 mg/m2), and oral prednisone...” PMID 34022150 ↗ May 2021 “Patients will receive a non-myeloablative lymphodepleting regimen consisting of fludarabine and cyclophosphamide (FC) to induce lymphocyte depletion and create an optimal...” NCT06912529 ↗ “Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1;...” NCT06176027 ↗ “Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care...” NCT04570423 ↗ “PL-doxorubicin 35-40 mg/m(2) and epirubicin 70 mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to...” NCT03022123 ↗ “The purpose of this clinical trial is to evaluate the efficacy and safety of Fluzoparib combined with docetaxel in sequential paclitaxel combined with cyclophosphamide for...” NCT07162051 ↗ “Axicabtagene Ciloleucel and A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced...” NCT03153462 ↗ “Conditioning: High dose TBI (1320 cGy TBI + Fludarabine 75 mg/m2 + Cyclophosphamide 120 mg/kg) or Intermediate Intensity regimen (400 cGy TBI + Fludarabine 150 mg/m2 +...” NCT04103879 ↗ “The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide,...” NCT00901615 ↗ “Post-transplantation Cyclophosphamide, Tacrolimus and Low-Dose ATG as GVHD Prophylaxis for Allogeneic Peripheral Stem Cell Transplantation for Adult Patients With Lymphoid...” PMID 33816524 ↗ Mar 2021 “The anthracycline may be either Epirubicin (body surface area-adjusted 50 mg/m²) or Liposomal Doxorubicin (body surface area-adjusted 30 mg/m²) combined with Cyclophosphamide...” NCT06914440 ↗ “Patients received a maximum of 2 cycles of the intravenous (IV) 5-drug regimen (clofarabine, etoposide,cyclophosphamide, PEG-asparaginase, and vincristine) plus intrathecal...” NCT00991133 ↗ “Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in...” NCT01389427 ↗ “Pre-treatment chemotherapy: Cyclophosphamide 500 mg/m² and Fludarabine 30 mg/m² will be administered intravenously on Days -5, -4, and -3 (with the day of Axicabtagene...” NCT06826118 ↗ “The chemotherapy entails the administration of multiple cycles of infusional doxorubicin, etoposide and vincristine chemotherapy (total of 3), alternating with cycles of...” NCT00001430 ↗ “short-course chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (CHOP-R) followed by 90-Y ibritumomab tiuxetan (RIT) with extended...” PMID 18981007 ↗ Nov 2008 “Study on the Treatment of Double/Triple-hit Diffuse Large B-cell Lymphoma With Chidamide and Lisaftoclax in Combination With Vepesidil, Rituximab, Cyclophosphamide, Adriamycin,...” NCT07552324 ↗ “CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg...” NCT02042391 ↗ “After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were...” NCT00147901 ↗ “Patients in R-miniCHOP group will receive rituximab 375 mg/m² on day 1, cyclophosphamide 400 mg/m², doxorubicin 25 mg/m², and vincristine 1 mg on day 2, and prednisone 40 mg/m²...” NCT05179733 ↗ “Patients will be able to receive the corticosteroid (CS) monotherapy or CS in combination with other immunosuppressive drugs (e.g. cyclophosphamide, mycophenolic acid) by a...” NCT07074951 ↗ “Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500...” NCT00392990 ↗ “R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate...” NCT01854372 ↗ “Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for...” NCT00563953 ↗ “Group one (control group) received R-CHOP standard chemotherapy {Rituximab, Cyclophosphamide, Hydroxyldaunorubicin (Doxorubicin)®, Vincristine (oncovin)®, prednisolone in the...” PMID 33394214 ↗ Jan 2021 “Six cycles of standard induction chemotherapy consisting of cyclophosphamide, vincristine, doxorubicin (or epirubicin), etoposide, and cisplatin administered according to the...” NCT07688252 ↗ “Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine,...” NCT00554164 ↗ “Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide...” NCT02063022 ↗ “with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin,...” NCT04845035 ↗ “Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in...” NCT02573935 ↗ “Patients received neoadjuvant chemotherapy with cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total...” PMID 29416986 ↗ Jan 2018 “Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin,...” NCT01290120 ↗ “Chemotherapy agents for consolidation include dexamethasone, vincristine, methotrexate, PEG-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available),...” NCT04501614 ↗ “A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of...” NCT03790891 ↗ “cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid...” NCT05498259 ↗ “Subjects will receive lymphodepletion pretreatment (Fludarabine/Cyclophosphamide), three SN301A intravenous infusions in a cycle (D0, D7, D14), with each subject receiving a...” NCT06652243 ↗ “A Pilot Study of Cyclophosphamide/Pegylated Liposomal Doxorubicin/Vincristine/Prednisone (CDOP) Plus Rituximab for Treatment of Elderly Patients With Previously Untreated...” NCT00120198 ↗ “Subjects will receive cyclophosphamide 200 to 300 mg/m2 and fludarabine 20 to 30 mg/m2 once daily for 3 days either on Days -5, -4 and -3 or on Days -4, -3 and -2 prior to...” NCT07315503 ↗ “We hypothesized that lymphodepletion, achieved with cyclophosphamide (Cy) and fludarabine (Flu), would promote in vivo expansion of the infused lymphocytes enhancing their...” PMID 17579184 ↗ Jun 2007 “Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three...” NCT02586025 ↗ “Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them...” NCT00863330 ↗ “First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of...” NCT02354690 ↗ “Rituximab combined with Chemotherapy (Rituximab, Cyclophosphamide, doxorubicin, Vincristine, Prednisone, Ifosfamide, Gemcitabine, cisplatin, Carboplatin, Etoposide, MESNA,...” NCT07187960 ↗ “4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks...” NCT01367288 ↗ “Neoadjuvant chemotherapy regimen will consist of six cycles of fluorouracil 500mg/m2 , epirubicin 75mg/m2 and cyclophosphamide 500mg/m2 administered intravenously at three week...” NCT03696004 ↗ “OPTIONAL: For subjects with any increase in lymphocyte count. Cyclophosphamide administered as 375 mg/m2 via intravenous infusion once during Cycle 1 after Day 5 of Belinostat therapy.” NCT02737046 ↗ “Other drugs are administered at starting doses (Etoposide 50 mg/m2 (Days 1-4), Doxorubicin 10 mg/m2 (Days 1-4), Vincristine 0,4 mg/m2 (Days 1-4) and Cyclophosphamide 750 mg/m2 (Day 5).” NCT06871007 ↗ “Patients received fludarabine and cyclophosphamide lymphodepleting preconditioning for three consecutive days-from day -5 (D-5) to day -3 (D-3)-prior to intravenous infusion of DQ1001” NCT07622862 ↗ “Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) followed by idiotype vaccine and granulocyte-macrophage colony-stimulating factor (GM-CSF).” NCT00005780 ↗ “AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery” NCT02620280 ↗ “Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3.” NCT00152113 ↗ “Chemotherapy will consist of: * four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by * twelve consecutive cycles of weekly paclitaxel 80 mg/mq” NCT04248998 ↗ “Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion.” NCT04637269 ↗ “Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.” NCT05341141 ↗ “low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation” NCT03608059 ↗ “AC (Doxorubicin and Cyclophosphamide) will be administered by IV infusion at 60 mg/m\^2 and 600 mg/m\^2 respectively on Days 1 and 15 of Cycles 1 and 2 for Arms F1, F2, G1 and G2.” NCT03800836 ↗ “Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.” NCT06517641 ↗ “The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg) the next day.” NCT03914768 ↗ “Patients received 375 mg/m(2) rituximab, 400 mg/m(2) cyclophosphamide, 25 mg/m(2) doxorubicin, and 1 mg vincristine on day 1 of each cycle, and 40 mg/m(2) prednisone on days 1-5.” PMID 21482186 ↗ Apr 2011 “Thalidomide, day 1 cycle 1, 100 mg/24 h. oral, in combination with cyclophosphamide and dexamethasone. If toxicity is <Grade 2, dose should be increased to 200 mg/24 h. in day 15” NCT00652041 ↗ “Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 (maximum total 2 mg) administered by IV infusion on Day 1 of each 21-day cycle.” NCT05189197 ↗ “mBuCy conditioning regimen（CCNU 250mg/m2/d -9d, Ara-C 2g/m2/d -8d; CDA 5 mg/m2/d -8d; Busulfan 3.2 mg/kg/d from -7 to -5 days; Cyclophosphamide 1.8 mg/m2/d from -4 to -3 days）” NCT06816134 ↗ “A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).” NCT05472610 ↗ “A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).” NCT04250324 ↗ “Low dose cyclophosphamide (metronomic cyclophosphamide), selectively reduce Treg population both in experimental models and in humans, but it does not affect effector T cells” NCT03844763 ↗ “Patients will receive a NMA-LD chemotherapy based on Cyclophosphamide 60 mg/kg IV (once daily on Days -5 and -4) and Fludarabine 25 mg/m2 IV (once daily on Days -5 to -1).” NCT05141474 ↗ “RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4)” NCT03412409 ↗ “postoperative adjuvant chemotherapy (100 mg/m² Epirubicin + 600 mg/m² Cyclophosphamide) combined with 200 mg Sintilimab intravenously every 3 weeks for a total of 1 year.” NCT07351487 ↗ “Vincristine, etoposide, carboplatin, and cyclophosphamide have been used in many protocols for brain tumors but the result was very poor in refractory or relapsed cases.” NCT01535183 ↗ “The purpose of this study is to evaluate the effects of the drug cyclophosphamide (CY) on inflammation and immune responses in individuals with Alzheimer's Disease (AD).” NCT00013650 ↗ “Participants with persistent proteinuria ≥ 1 g/day after 8 weeks of corticosteroid monotherapy will receive 0.8-1.0 g of intravenous cyclophosphamide (CTX) every 4 weeks” NCT03418779 ↗ “Vincristine 1.4 mg/m2 (2 mg cap) IV on Day 1, Doxorubicin 10 mg/m2/day CIVI on Days 1-4, Etoposide 50 mg/m2/day CIVI on Days 1-4, Cyclophosphamide 750 mg/m2 IV on Day 5.” NCT04002947 ↗ “cyclophosphamide and fludarabin conditioning , followed by a target dose of 1 x 10exp6 of autologous, genetically modified, anti-CD19 CAR-T cells per kg of body weight.” NCT06649227 ↗ “5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)” NCT00531973 ↗ “Multi-agent chemotherapy including vincristine, prednisone, daunorubicin, cyclophosphamide, pegaspargase, cytarabine, 6-MP, MTX, and dexamethasone per protocol phases.” NCT07454226 ↗ “The chemotherapy regimen is AC-T: epirubicin 100mg/m2, cyclophosphamide 600mg/m2, every 3 weeks for 4 cycles; followed by paclitaxel 80mg/m2, every week for 12 cycles.” NCT07197697 ↗ “Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the most effective front-line therapies to treat indolent B-cell lymphoma.” PMID 21931035 ↗ Sep 2011 “Patients will receive a 21-day course of pentostatin (intravenous infusion on days 1, 8, and 15; 4 mg/m\^2 per dose) and daily oral cyclophosphamide (200 mg per day).” NCT00923845 ↗ “Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide” NCT02098512 ↗ “Fludarabine/Busulfan and Post-infusion Cyclophosphamide as Conditioning for Adult Patients With Lymphoid Malignancies Undergoing Allogeienc Stem Cell Transplantation” NCT01435447 ↗ “Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma” NCT00204659 ↗ “Rituximab 375mg/m2 D1; cyclophosphamide 750mg/m2 D2; adriamycin 50 mg/m2 D2 vincristine 1.4mg/m(Max 2mg) D2; prednisone 100mg/d D2-6; Zanubrutinib 160 mg, bid D1-21” NCT06005870 ↗ “STC-1010 administered with immunostimulants (IS) in low-dose (cyclophosphamide and GM-CSF) and standard of care (SOC) therapy (mFOLFOX6 with or without bevacizumab)” NCT06934538 ↗ “standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles.” NCT04677816 ↗ “CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) is currently regarded as a standard chemotherapy regimen for patients with newly diagnosed NHL.” NCT00930605 ↗ “Intravenous administration: Rituximab 375 mg/m2, Cyclophosphamide 400 mg/m2, Doxorubicin 25 mg/m2, Vincristine 1 mg, and Oral administration: Prednisone 40 mg/m2” NCT07215585 ↗ “According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.” NCT03638206 ↗ “Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour” NCT01385891 ↗ “Dose dense doxorubicin plus cyclophosphamide followed by paclitaxel (ddAC/ddT) for 8 cycles, administered per USPI (Unites States Prescribing Information) Label” NCT05256745 ↗ “Specified in the protocol were vincristine/doxorubicin/dexamethasone (VAD), idarubicin/dexamethasone (ID) and cyclophosphamide/doxorubicin/dexamethasone (CAD).” NCT02288741 ↗ “Patients will receive Fludarabine (30mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3, followed by Anti-CD19 CAR NK cells infusion.” NCT06318533 ↗ “Epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 3 weeks for 4 cycles followed by paclitaxel (175 mg/m2) every 3 weeks for 4 cycles (EC-P regimen).” PMID 36826820 ↗ Feb 2023 “Epirubicin (75-100 mg/m²) in combination with cyclophosphamide (600 mg/m²), administered by intravenous infusion every 21 days (Q3W), for a total of 4 cycles.” NCT07254858 ↗ “sequential intravenous administration of Rituximab, Cyclophosphamide (specifically dose-adjusted for end-stage renal disease), and rabbit Thymoglobulin (rATG)” NCT07607197 ↗ “The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.” PMID 22014006 ↗ Oct 2011 “Drug: Cyclophosphamide and fludarabine Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to BAFF-R CART cells infusion on Day 0.” NCT07022197 ↗ “RNK001 infusion was supported by IP IL-2 in six patients, and was preceded in one patient by lymphodepleting chemotherapy with cyclophosphamide/fludarabine.” PMID 41289795 ↗ Nov 2025 “Patients who are considered medical candidates for doxorubicin should receive CHOP chemotherapy (Cyclophosphamide, doxorubicin, vincristine and prednisone).” NCT00193440 ↗ “This will be followed by a third part which includes about nine months of treatment with cisplatin, adriamycin, etoposide, cyclophosphamide, and topotecan.” NCT00135135 ↗ “Drug: Cyclophosphamide Cyclophosphamide will be given at a dose of 300 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD2219-CAR-T cells.” NCT06834529 ↗ “prednisolone (PRED) (0.8mg/kg/d) plus Cyclophosphamide (CTX) (1.5-2mg/kg/d) followed by Azathioprine (AZA) (1-1.5mg/kg/d) as induction-maintenance therapy” NCT02954939 ↗ “Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine” NCT03319901 ↗ “Bortezomib-containing chemotherapy regimen (e.g. cyclophosphamide, bortezomib, and dexamethasone (CyBorD)) according to the institutional standard of care” NCT04973137 ↗ “Administration of total lymphatic irradiation, antithymocyte globulins, and high dose cyclophosphamide, followed by the infusion of autologous stem cells.” NCT02728271 ↗ “Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day” NCT06903117 ↗ “Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation.” NCT01208896 ↗ “Cycle 1-4: Epirubicin i.v. 90 mg/m2, Cyclophosphamide i.v. 600 mg/m2 (One cycle = 21 days); Cycle 5-8: Docetaxel i.v. 100mg/m2 (One cycle = 21 days) .” NCT04576143 ↗ “Before initiating ThisCART19A infusion, subjects will be administered lymphodepletion chemotherapy composed of fludarabine、cyclophosphamide and VP-16.” NCT05679687 ↗ “Patient will receive Dara-CyBorD (Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone) for at least 6 cycles, and then Daratumumab maintainance.” NCT06418477 ↗ “All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.” NCT03142646 ↗ “At months 2, 4, and 6, patients received cyclophosphamide adjusted for age and renal function (1.0-2.0 mg/kg/day for 30 days, maximum dose 100 mg/d).” NCT05782933 ↗ “VDCLP regimen (vincristine, daunorubicin, cyclophosphamide, L-asparaginase, and prednisone) combined with CM313 at the RP2D during induction therapy.” NCT07585734 ↗ “Approximately 3-5 days prior to CD5 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion.” NCT07022964 ↗ “The 5 chemotherapy drugs used in the Induction part of treatment are vincristine, cisplatin, cyclophosphamide, etoposide and high-dose methotrexate.” NCT02875314 ↗ “Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.” NCT01458548 ↗ “Standard treatment will include: * CAR T-cell therapy (either axicabtagene-ciloleucel or lisocabtagene maraleucel) * Cyclophosphamide * Fludarabine” NCT05934448 ↗ “patients enrolled in this study will receive 20 mg/kg of cyclophosphamide for solid tumor or 20-60 mg/kg of cyclophosphamide for hematological tumor” NCT03619954 ↗ “Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3.” NCT00186823 ↗ “Fludarabine injection (30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before RN1201 infusion.” NCT07105735 ↗ “Prior to infusion of the LCAR- F33S cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.” NCT07100067 ↗ “Prior to infusion of the LCAR-M61SQ cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.” NCT06888752 ↗ “Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide, and dexamethasone in patients with Relapsed/Refractory Multiple Myeloma” NCT04896658 ↗ “Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide” NCT02766868 ↗ “Brentuximab Vedotin, 1.8mg/kg/dose, d0、Rituximab, 375 mg/m2, d0、Cyclophosphamide, 750 mg/m2, d1、Doxorubicin, 50 mg/m2, d1、Prednisone, 60mg/m2, d1-5” NCT06925555 ↗ “Dose Adjusted - Etoposide Prednisone Vincristine Cyclophosphamide Doxorubicin - Rituximab (DA-EPOCH-R) and nivolumab are both feasible treatments.” NCT03620578 ↗ “Fludarabine (30 mg/m2 per day, from D-6 to D-3) and cyclophosphamide (2400 mg/ m2 x 2 days, on days -6 and -5) are administered as an IV infusion.” NCT06889766 ↗ “R-HDS : Rituximab supplemented high-dose (Cyclophosphamide,Ara-C, Methotrexate, Etoposide, Cis-Platin) sequential chemotherapy with autografting.” NCT00355199 ↗ “A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity.” NCT02223312 ↗ “High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy” NCT01639339 ↗ “Intravenous infusions of cyclophosphamide and fludarabine administered for 3 consecutive days 3-5 days prior to receive lisocabtagene maraleucel.” NCT07711483 ↗ “A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity.” NCT02709993 ↗ “cyclophosphamide 120 mg/kg, fludarabine 75mg/m2 and TBI 12 Gy or cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg and TBI 4 Gy” NCT03913026 ↗ “CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10” NCT01998906 ↗ “Lymphodepletion chemotherapy with fludarabine (25 mg/m²/day) and cyclophosphamide (250 mg/m²/day) should be administered for 2-3 consecutive days” NCT07306156 ↗ “Patients receive oral cyclophosphamide on days 1-14 (or IV on days 1 and 8) and epirubicin hydrochloride IV and fluorouracil IV on days 1 and 8.” NCT00433589 ↗ “Treatment consists of a conditioning regimen (cyclophosphamide and fludarabine), a single infusion of E7 TCR-T cells, and adjuvant aldesleukin.” NCT05686226 ↗ “A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of Novel CAR-T cells” NCT04191941 ↗ “both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.” NCT02789332 ↗ “Subjects assigned to receive lymphodepleting preconditioning (LDC) will receive chemotherapy cyclophosphamide ahead of ACE1831 administration.” NCT07314567 ↗ “Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma” NCT00126243 ↗ “Subjects assigned to receive lymphodepleting preconditioning (LDC) will receive chemotherapy cyclophosphamide ahead of ACE1831 administration.” NCT07061938 ↗ “Prior to infusion of the LCAR-G08, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.” NCT06197178 ↗ “Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2” NCT00574730 ↗ “Cyclophosphamide: 750 mg/m2, endovenous, in 30 minutes, day 5, after ending the continuous infusion of adriamycin, etoposide and vincristine.” NCT01066429 ↗ “The schedule of administering cyclophosphamide and DNAmix complex composite preparation is calculated according to the resulting time points.” NCT06361264 ↗ “CY (cyclophosphamide) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).” NCT02188368 ↗ “Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide.” NCT00145587 ↗ “fludarabine and cyclophosphamide Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days” NCT03711864 ↗ “Standard first-line chemotherapy regimen consisting of doxorubicin (an anthracycline antibiotic) and cyclophosphamide (an alkylating agent).” NCT07671547 ↗ “Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks.” NCT06977893 ↗ “Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1.” NCT01049854 ↗ “Administration of dendritic cells pulsed with autologous tumor lysate combined with cyclophosphamide in patients with mesothelioma was safe” PMID 26652184 ↗ May 2016 “Drug: Cyclophosphamide Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 2 of Cycle 1-6, during induction treatment.” NCT04023916 ↗ “Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes” NCT02846584 ↗ “Fludarabine: 30 mg/m² per day, once daily for 3 consecutive days; Cyclophosphamide: 300 mg/m² per day, once daily for 3 consecutive days;” NCT07337785 ↗ “Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days” NCT00117598 ↗ “3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100)” NCT02181101 ↗ “Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2.” NCT02066220 ↗ “P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series” NCT02572492 ↗ “Subjects with lymphoblastic leukemia will receive an alternative regimen of cyclophosphamide, a routine chemotherapy on days -6 and -5” NCT06315309 ↗ “The standard chemotherapy regimen is the AC-T regimen (4 cycles of epirubicin plus cyclophosphamide, followed by 4 cycles of a taxane)” NCT07622836 ↗ “Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) plus rituximab and campath every 3 weeks for up to 6 cycles” NCT01030900 ↗ “CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.” NCT06549296 ↗ “Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation” NCT00063817 ↗ “Cyclophosphamide 500 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion.” NCT00626626 ↗ “The starting dose is carboplatin AUC 5mg/ml\*min, cyclophosphamide 600mg/m2 and atezolizumab 840 mg, all administered intravenously.” NCT02914470 ↗ “Pentostatin 4 mg/m2/day IV on days -9 and -5, cyclophosphamide 5 mg/kg orally daily on days -9 through -2 (Closed with amendment L)” NCT02579967 ↗ “Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.” NCT00069238 ↗ “conditioning regimen before autologous stem cell transplantation consists of thiotepa, bulsulfan, and cyclophosphamide from day -9.” NCT06625359 ↗ “Cyclophosphamide will be administered on Day 5 with initial dose based on initial CD4+ cell count to minimize hematologic toxicity.” NCT00799136 ↗ “Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.” NCT03076437 ↗ “Lymphodepletion Conditioning: Chemotherapy (Cyclophosphamide + Fludarabine) before cell infusion to clear lymphocytes in the body.” NCT07366658 ↗ “those who do not will receive QL1706 Q3W + epirubicin Q3W + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy before surgery.” NCT07372079 ↗ “Lymphodepleting chemotherapy ( fludarabine and cyclophosphamide) administered pre-infusion to facilitate CAR-NK cell engraftment.” NCT07589517 ↗ “Busulfan/Cyclophosphamide, "standard" conditioning regimen as a control group. including Bu3.2mg/kg -5\~-3d; Cy 80mg/kg，-2\~-1d。” NCT06133556 ↗ “Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.” NCT06532630 ↗ “BACOPP-D regimen which includes cyclophosphamide, adriamycin, dacarbazine, procarbazine, prednisolone, bleomycin and vincristine” NCT00188149 ↗ “Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells Lymphodepleting regimen, Cyclophosphamide 250mg/m2 IV on day -5 to -3” NCT06728189 ↗ “Doxorubicin Injection at 50mg/m2 and Cyclophosphamide Injection at 500 mg/m2, administered intravenously respectively once daily” NCT05673629 ↗ “3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy” NCT03399747 ↗ “Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered.” NCT00206466 ↗ “Participants received a standard conditioning regimen consisting of total body irradiation, cyclophosphamide, thiotepa and ATG.” NCT00152139 ↗ “Cyclophosphamide，Fludarabine，CART-138/BCMA /19/more cells Cyclophosphamide: 300 mg/m2 IV over 30 minutes on days -5 , -4,and -3” NCT03196414 ↗ “Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)” NCT01949818 ↗ “Docetaxel plus trastuzumab for 9 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide in both groups.” PMID 29852043 ↗ Sep 2018 “4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel+ Metformin (1000 mg twice daily) followed by surgery.” NCT04559308 ↗ “Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes.” NCT02930967 ↗ “The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.” NCT05667402 ↗ “(doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)” NCT02688803 ↗ “Immunochemtherapy phase: CR CHOP for 4 cycles: chidamide 20mg d1,4,8,11,rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1” NCT06674096 ↗ “The induction therapy is a combination of Blinatumomab(Blina), Vindesine(VDS), Cyclophosphamide(CTX) and Dexamethasone(DXM).” NCT06742515 ↗ “Docetaxel 75 mg/m2, Cyclophosphamide 600 mg/m2 and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles.” NCT03705429 ↗ “six cycles of intravenous vinorelbine 25 mg/m2 on days 1, 8, and 15, and daily oral cyclophosphamide 25 mg/m2, on days 1-28” PMID 31562043 ↗ Sep 2019 “Prior to CAR-T cell infusion, subjects will receive lymphodepleting chemotherapy based on fludarabine and cyclophosphamide.” NCT07240857 ↗ “Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo” NCT01005745 ↗ “Cyclophosphamide is given by vein over about 15 minutes on day 5 immediately after the chemotherapy infusion is completed.” NCT00114738 ↗ “short-course etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with dose-dense rituximab (SC-EPOCH-RR)” PMID 20130244 ↗ Feb 2010 “Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1” NCT04881838 ↗ “Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d” NCT04880746 ↗ “HLX01 plus cyclophosphamide, doxorubicin, vincristine, and prednisone (H-CHOP) and reference rituximab plus CHOP (R-CHOP)” PMID 32299513 ↗ Apr 2020 “4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks” NCT02001519 ↗ “conventional chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone) and rituximab (R-CHOEP-14)” PMID 23168367 ↗ Nov 2012 “Epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks for 4 cycles (Cycles 5-8)” NCT04398914 ↗ “Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days” NCT06642025 ↗ “Cyclophosphamide 750mg/m² + Doxorubicin 50mg/m² + Vincristine 1.4mg/m² [max 2mg] IV day 1 + Prednisone 100mg PO days 1-5” NCT07538180 ↗ “R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles” NCT01865110 ↗ “Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna.” NCT01328496 ↗ “A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle” NCT02705703 ↗ “Participants receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) followed by CAR-NK administration.” NCT07480954 ↗ “Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle” NCT00268853 ↗ “alternating cyclophosphamide, vincristine and idarubicin alternating with another 3 cycles of carboplatin and etoposide” NCT03475121 ↗ “CB-012 allogeneic CAR-T cell therapy targeting CLL-1 Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion” NCT06128044 ↗ “The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.” NCT05933967 ↗ “R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.” NCT04661007 ↗ “type of chemotherapy called cyclophosphamide, which will be given intravenously on the sixth day before the transplant” NCT00864227 ↗ “cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 (maximum dose 2 mg) intravenously on day 1” PMID 31126528 ↗ Jun 2019 “Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.” NCT04097301 ↗ “neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab” NCT01340430 ↗ “Drug: Fludarabine + Cyclophosphamide+Oxaliplatin Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 300mg/m²/day×3 days” NCT05933668 ↗ “Conditioning chemotherapy: Cyclophosphamide 250 mg/m\^2 and fludarabine 30 mg/m\^2 IV infusion on days -5, -4, and -3” NCT04662099 ↗ “Patients in this arm will receive a low dose of cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51” NCT02187367 ↗ “Hyper-CVAD-A: Cyclophosphamide ,Vincristine , Doxorubicin , Dexamethasone ; Hyper-CVAD-B: Methotrexate , Cytarabine .” NCT07564453 ↗ “including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.” NCT05247203 ↗ “liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD)” NCT02858999 ↗ “Drug: Cyclophosphamide Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days” NCT04537442 ↗ “Cyclophosphamide is a medication mainly used in chemotherapy. It is an alkylating agent of the nitrogen mustard type” NCT02838992 ↗ “lymphodepleting therapy with fludarabine (adjusted based on renal impairment) and cyclophosphamide daily for 3 days.” NCT06655896 ↗ “epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)” NCT04066790 ↗ “recommended chemotherapy regimen consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day)” NCT04639739 ↗ “Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone” NCT01430013 ↗ “Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3.” NCT06464679 ↗ “Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3.” NCT06469190 ↗ “second line immune-modulator regimens (CAMC, clarithromycin (CAM) and low-dose cyclophosphamide) will be prescribed” NCT07144657 ↗ “Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3.” NCT05673447 ↗ “Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3.” NCT06792799 ↗ “5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles” NCT01270373 ↗ “comprised intravenous Doxorubicin 60 mg/m²/cycle with intravenous Cyclophosphamide 600 mg/m²/cycle for four cycles” NCT06186700 ↗ “non-myeloablative lymphodepletion chemotherapy with cyclophosphamide and fludarabine administered on Days -4 to -2” NCT07593820 ↗ “Drug: cyclophosphamide. On days -4 through -2, cyclophosphamide (250mg/m2) will be infused for 3 consecutive days” NCT03330834 ↗ “Post-transplantation cyclophosphamide (PTCY) is considered as major graft versus host disease (GVHD) prophylaxis.” NCT06000982 ↗ “Metronomic dosage of Cyclophosphamide during 3 weeks (50mg/day orally) as reported 15, before specific treatment.” NCT01159288 ↗ “Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide.” NCT04237428 ↗ “Drug: Cyclophosphamide (600 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.” NCT05656079 ↗ “D1 : Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.” NCT03931642 ↗ “Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.” NCT00698191 ↗ “Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.” NCT06316076 ↗ “Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion.” NCT01659151 ↗ “Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin (ATG) and Tacrolimus” NCT06705062 ↗ “Drug1 : Fludarabine + Cyclophosphamide Drug2 :Interleukin 2 Drug3 :KRAS-specific Autologous TCR-T cell injection” NCT06767046 ↗ “lymphodepleting chemotherapy with cyclophosphamide and fludarabine once a day for 3 days via IV about 2-4 hours.” NCT05583149 ↗ “cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.” NCT03949634 ↗ “The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna.” NCT00179816 ↗ “Drug: Cyclophosphamide: Two days before cell infusion, patient will be treated with Cyclophosphamide for 3 days” NCT04766840 ↗ “Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)” NCT06243159 ↗ “Cyclophosphamide 500 mg - 2000 mg/m2 (day 2) with or without Fludarabine 30 mg/m2 /day, 4 days (day 6, 5, 4, 3)” NCT02644655 ↗ “Cyclophosphamide: 300-450mg/m², dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 60minutes” NCT05438667 ↗ “Drug: Cyclophosphamide Recommendation: 250-300 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline.” NCT06209671 ↗ “Cyclophosphamide is nontoxic to hematopoietic stem cells and can selectively deplete the alloreactive T cells.” NCT03395860 ↗ “Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone” NCT07608978 ↗ “Example regimen: fludarabine (Days -5 to -3) and cyclophosphamide (Days -5 to -4) prior to CAR-NK infusion.” NCT07480928 ↗ “R-HDS (cyclophosphamide, cytarabine, and etoposide) supported by autologous stem-cell transplantation (ASCT)” PMID 26282634 ↗ Aug 2015 “CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.” NCT01796002 ↗ “Pola-R-CHP is a combination of rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin” NCT06743945 ↗ “lumiliximab added to fludarabine, cyclophosphamide, and rituximab (FCR) in previously treated CLL patients.” PMID 19843887 ↗ Oct 2009 “dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R)” PMID 32453640 ↗ May 2020 “patients receive doxorubicin hydrochloride IV over 20 minutes and cyclophosphamide IV over 1 hour on day 1.” NCT00647218 ↗ “CVAD is the acronym of the drugs in course a: cyclophosphamide, vincristine, doxorubicin and dexamethasone.” NCT05581030 ↗ “infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (EPOCH-R)” PMID 24224624 ↗ Nov 2013 “concomitantly administered nonmyeloablative fludarabine, cyclophosphamide and total body irradiation (TBI)” NCT00004143 ↗ “bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc)” NCT01652261 ↗ “Drug: Fludarabine + Cyclophosphamide Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days” NCT06515314 ↗ “Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.” NCT05112536 ↗ “chemotherapy - fludarabine (Days -5 to -3) and cyclophosphamide (Days -5 to -4), prior to CAR-NK infusion.” NCT07510802 ↗ “high-dose rituximab combined with thiotepa, busulfan, and cyclophosphamide (R-TBC) for ASCT was conducted.” PMID 25204639 ↗ Sep 2014 “Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte” NCT01458730 ↗ “Cyclophosphamide is a commonly used alkylated chemotherapy drug,It's also an important immunosuppressant.” NCT05936086 ↗ “Docetaxel: 75mg/m2, d1, q3w\*6, Epirubicin 75mg/m2, d1, q3w\*6 and Cyclophosphamide: 500mg/m2, d1, q3w\*6” NCT02532400 ↗ “Patients receive fludarabine phosphate(300 mg/m\^2) and cyclophosphamide (30 mg/m\^2) IV on days -5 to -3” NCT03672851 ↗ “Drug: Cyclophosphamide Recommendation: 250-300 mg/kg (D-5\~D-3), determined by tumor burden at baseline.” NCT05410041 ↗ “Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (1000mg/m2 per day) on day -3.” NCT06337474 ↗ “with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days” NCT00910650 ↗ “CHOP regimen includes the administrations of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.” NCT07496229 ↗ “Drug: Cyclophosphamide Recommendation: 250-300 mg/m2 (D-5\~D-3), determined by tumor burden at baseline.” NCT05563545 ↗ “CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days” NCT03576521 ↗ “Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.” NCT06718738 ↗ “CB-010 allogeneic CAR-T cell therapy, Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion” NCT06752876 ↗ “cyclophosphamide (Cy, 1000 mg/m2/day, day -6 to -5), and fludarabine (Flu, 25 mg/m2/day, day -6 to -2)” NCT04221971 ↗ “Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV)” NCT03485118 ↗ “Cyclophosphamide: An alkylating agent that inhibits the synthesis of DNA and proteins in cancer cells.” NCT06829771 ↗ “Drug:Cyclophosphamide Recommendation: 300mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.” NCT07406984 ↗ “Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC.” NCT00394251 ↗ “CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles” NCT01649856 ↗ “The patient will receive cyclophosphamide 60mg/kg on day -3 and day -2 prior to the NK cell infusion.” NCT03242603 ↗ “AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.” NCT00206518 ↗ “Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.” NCT06006390 ↗ “Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses” NCT06170294 ↗ “Cyclophosphamide 200 mg/m(2) intravenous will be given on Day 0, prior to the first dose of AMP-224.” NCT02298946 ↗ “Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses” NCT06348797 ↗ “Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.” NCT07247396 ↗ “CEOP, cyclophosphamide 750 mg/m2, epirubicin 70 mg/m2, vincristine 1.4 mg/m2 [maximum 2 mg] on day 1” PMID 32349779 ↗ Apr 2020 “CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1” NCT01664975 ↗ “Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses” NCT03874897 ↗ “Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab” NCT06535893 ↗ “Cyclophosphamide (Cy) + Doxorubicin (ADM) + Vincristine (VDS) + Prednisone (Pred) ]± Rituximab (R)” NCT06520163 ↗ “cyclophosphamide (two pulses of 10 mg/kg, corrected according to renal function, on days 4 and 17)” NCT06680349 ↗ “Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes” NCT02265770 ↗ “Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2” NCT01642771 ↗ “TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.” NCT02464774 ↗ “Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI” NCT06490562 ↗ “5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles” NCT00524303 ↗ “Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine.” NCT05639972 ↗ “Combination of seclidemstat with topotecan and cyclophosphamide, as assigned per parent protocol” NCT05266196 ↗ “IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days” NCT05292898 ↗ “Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1” NCT01501487 ↗ “standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2)” NCT01537536 ↗ “TC-G203 CAR-T cells Treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide.” NCT07242417 ↗ “Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.” NCT05040906 ↗ “Drug: Cyclophosphamide Part of the non-myeloablative lymphocyte-depleting preparative regimen.” NCT05868915 ↗ “four cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks intravenously” PMID 42372741 ↗ Jul 2026 “lymphodepletion regimen that includes 300 mg per square meter of intravenous cyclophosphamide.” NCT05634785 ↗ “Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd” NCT02879526 ↗ “doxorubicin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively” NCT03283384 ↗ “Cyclophosphamide- 750 mg/m\^2 IV over approximately 1 hour on D1 every 21 days for 2-6 cycles” NCT03264131 ↗ “Cyclophosphamide 500 mg/m2/day for NHL and 250 mg/m2/day for ALL given IV from day -5 to -3.” NCT06027957 ↗ “standardised conditioning regimen involving Fludarabine, Cyclophosphamide, Thiotepa, and TBI” NCT07372885 ↗ “A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered” NCT07275736 ↗ “receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV” NCT05675813 ↗ “VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone)” NCT01173887 ↗ “A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered” NCT03720496 ↗ “R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))” NCT02054559 ↗ “Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim” NCT02142049 ↗ “Fludarabine + Cyclophosphamide administered on Days -5, -4, and -3 prior to CAR-NK infusion” NCT07467863 ↗ “Cyclophosphamide, Vincristine, and Prednisone (CVP) Followed by Iodine-131 Anti-B1 Antibody” NCT01663714 ↗ “Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion” NCT01302392 ↗ “* Cyclophosphamide: 2100 mg/m\^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2.” NCT01696669 ↗ “Fludarabine + Cyclophosphamide administered on Days -5, -4, and -3 prior to CAR-NK infusion” NCT07641023 ↗ “fludarabine (Days -5 to -3) and cyclophosphamide (Days -5 to -4) prior to CAR-NK infusion.” NCT07627711 ↗ “Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone” NCT06072131 ↗ “dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone” NCT05996185 ↗ “Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle” NCT00868413 ↗ “Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2.” NCT06611813 ↗ “Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP)” NCT01352338 ↗ “A scheme with liposomal doxorubicin (Caelyx) and cyclophosphamide (endoxan) will be used.” NCT00284336 ↗ “50 mg cyclophosphamide (Sendoxan®, Baxter A/S) is administered p.o. twice a day bi-weekly” NCT00197912 ↗ “Chemotherapies: busulfan, fludarabine, melphalan, cyclophosphamide, thiotepa, clofarabine” NCT04761770 ↗ “TC-D101 CAR-T treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide.” NCT07246304 ↗ “vincristine (Oncovin), cyclophosphamide, procarbazine, etoposide and prednisone (BEACOPP)” PMID 28601705 ↗ Jun 2017 “Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.” NCT03086564 ↗ “Chidamide Plus R-CHOP (Rituximab、Cyclophosphamide、Doxorubicin、Vincristine and Prednisone)” NCT06891157 ↗ “oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle” NCT03971045 ↗ “Cyclophosphamide (750 mg/m\^2) + doxorubicin (50 mg/m\^2) + prednisone (100 mg days 2-6)” NCT06040320 ↗ “Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles” NCT01472146 ↗ “Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide” NCT05877599 ↗ “Patients will receive Fludarabine and Cyclophosphamide for lymphodepletion conditioning.” NCT06421701 ↗ “R-CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine and prednisone” NCT02012088 ↗ “Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types.” NCT04221035 ↗ “AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks” NCT04170465 ↗ “The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.” NCT05234684 ↗ “Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days.” NCT00176826 ↗ “Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy.” NCT07145450 ↗ “cyclophosphamide 500mg D1-8-15 + thalidomide 100-200mg D1-28 + dexamethasone 40mg/week” NCT03792620 ↗ “Drug: Cyclophosphamide (CY) lymphodepletion: 300 mg/m² IV daily ×2 days (Cycle 1 only)” NCT07410676 ↗ “cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3” NCT04508842 ↗ “Cyclophosphamide 250 mg/m2 and fludarabine 30 mg/m2 IV infusion on day -5, -4, and -3.” NCT07168291 ↗ “Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.” NCT05748197 ↗ “Vincristine, daunorubicin, cyclophosphamide, pegaspargase, prednisone, and venetoclax.” NCT07495631 ↗ “cyclophosphamide was calculated at 600mg/m2 body surface area by intravenous micropump” NCT06705127 ↗ “Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles” NCT02441933 ↗ “IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)” NCT01010854 ↗ “rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1” NCT01502982 ↗ “Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 every 2 weeks x 4 cycles” NCT02789657 ↗ “WITH Fludarabine (IV) + Cyclophosphamide (IV), administered prior to CAR-NK infusion.” NCT07410494 ↗ “12-week EC regimen (epirubicin 80mg/m² + cyclophosphamide 600mg/m², IV Q3W, 4 cycles)” NCT07491822 ↗ “First Phase of Neoadjuvant Chemotherapy: Epirubicin + Cyclophosphamide + Toripalimab.” NCT06682195 ↗ “lymphodepleting chemotherapy consisting of cyclophosphamide combined with fludarabine” NCT07535138 ↗ “after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide” NCT01947322 ↗ “Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle.” NCT00486759 ↗ “cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin” NCT01091168 ↗ “Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;” NCT04572308 ↗ “Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once;” NCT05075681 ↗ “IAA with Cyclophosphamide (3 g/m2), thiotepa (240 mg/m2) and carboplatin (800 mg/m2)” NCT00448266 ↗ “Brentuximab Vedotin Etoposide Cyclophosphamide Doxorubicin Dacarbacine Dexamethasone” NCT06919679 ↗ “followed by 5-FU, epirubicin, and cyclophosphamide (FEC) every 3 weeks for 4 cycles” NCT00110695 ↗ “Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel” NCT04667793 ↗ “Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.” NCT06532799 ↗ “Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.” NCT06532812 ↗ “A combination of fludarabine and cyclophosphamide will be used for lymphodepletion.” NCT05768529 ↗ “Cyclophosphamide (C), intravenous infusion, 1200mg/m2, D1, odd cycle administration” NCT06699472 ↗ “post-transplant cyclophosphamide for prevention of Graft Versus Host Disease (GVHD)” NCT02053545 ↗ “Drug: Cyclophosphamide (500 mg/m²) + Fludarabine (30 mg/m²), IV on Days -5, -4, -3.” NCT06902012 ↗ “3-day chemotherapy regimen of fludarabine and cyclophosphamide for lymphodepletion” NCT06027983 ↗ “BeEAC (Bendamustine, Cytarabine, Etoposide, Cyclophosphamide) conditioning regimen” NCT03315520 ↗ “Biological: CAR-γδT; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;” NCT04796441 ↗ “recommended Fludarabine and cyclophosphamide (unless contra-indicated for subject)” NCT03610724 ↗ “Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles” NCT01176799 ↗ “Epirubicin + cyclophosphamide + Benmelstobart are administered by intravenous drip” NCT06874933 ↗ “Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles” NCT01042379 ↗ “All patients received 50 mg twice daily cyclophosphamide 1 week on and 1 week off” PMID 28662235 ↗ Jan 2018 “Epirubicin 90 mg/mq + Cyclophosphamide 600 mg/mq i.v. every 3 weeks for 3 courses” NCT04659551 ↗ “the patient will be pretreated with fludarabine and cyclophosphamide (FC) regimen” NCT06464185 ↗ “conditioning premedication regimen consisting of cyclophosphamide and fludarabine” NCT06472479 ↗ “vincristine, cyclophosphamide, cisplatin, etoposide with or without methotrexate” NCT06193759 ↗ “Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine)” NCT03570892 ↗ “Albumin Paclitaxel + Carboplatin\*4 Followed by Epirubicin + Cyclophosphamide\*4” NCT07256964 ↗ “cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone” NCT00554502 ↗ “Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26” NCT02451774 ↗ “Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days” NCT01858571 ↗ “Cycle 1: VDCP regimen (Vincristine, Daunorubicin, Cyclophosphamide, Prednisone).” NCT06930105 ↗ “Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days” NCT05876065 ↗ “High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin” NCT00851110 ↗ “Cyclophosphamide 14.5 mg/kg intravenously prior to transplant on Days -6 and -5” NCT04187105 ↗ “R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, and prednisone)” NCT00582725 ↗ “Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)” NCT05051891 ↗ “Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (day 1), IV (in the vein)” NCT01660542 ↗ “Month 2: Oral cyclophosphamide (2.0 mg/kg/d, maximum dose 100mg/d) for 30 days” NCT04424862 ↗ “Cyclophosphamide (250 mg/m2/day) will be administered intravenously for 3 days” NCT07004647 ↗ “Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles” NCT02539017 ↗ “including cyclophosphamide(CYC), methotrexate(MTX) and azathioprine(AZA) etc.” NCT03096275 ↗ “All patients will be treated with fludarabine and cyclophosphamide for 3 days” NCT04336501 ↗ “R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone)” NCT02858258 ↗ “rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone” NCT03293173 ↗ “Patients will receive Fludarabine and Cyclophosphamide on day -5, -4, and -3” NCT07298590 ↗ “Cyclophosphamide 50 mg/kg intravenously day+3 and +4 (total dose:100 mg/kg).” NCT03270748 ↗ “receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses” NCT00003953 ↗ “chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes” NCT02930993 ↗ “epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab” NCT04094896 ↗ “Pretreatment with fludarabine and cyclophosphamide CAR-GPC3 T Cells infusion” NCT03980288 ↗ “Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.” NCT05886491 ↗ “Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1,every 3 weeks” NCT06433362 ↗ “doxorubicin 35 mg/m2 and cyclophosphamide 1250 mg/m2 intravenously on day 1” PMID 30658935 ↗ Jan 2019 “FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2)” NCT03881774 ↗ “FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2)” NCT03881761 ↗ “Busulfan, carmustine and cyclophosphamide will be given to you for 5 days.” NCT05425654 ↗ “Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2” NCT02268045 ↗ “Cisplatin, vincristin, etoposide, cyclophosphamide, high-dose methotrexate” NCT07291102 ↗ “The patients then receive fludarabine and cyclophosphamide on days-5 to-3.” NCT03767725 ↗ “R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone” NCT05058404 ↗ “Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally.” NCT02517918 ↗ “Cyclophosphamide (1,000 mg/m2, intravenously, for 1 hour - days 43 and 71)” NCT03390387 ↗ “Cyclophosphamide, orally, at 400 mg on Days 1, 8, 15 of each 28-day cycle.” NCT03215524 ↗ “treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.” NCT06771180 ↗ “Cyclophosphamide 60 ㎎/㎏ in D5W 200 ㎖ i.v. over 1-2 hours on days -3 and -2” NCT00774280 ↗ “cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days” NCT01526512 ↗ “Metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs.” PMID 30413837 ↗ Nov 2018 “Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide” NCT07383818 ↗ “cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles” NCT05862610 ↗ “During Cycle 2, participants will receive etoposide and cyclophosphamide.” NCT05326516 ↗ “R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone)” NCT03023878 ↗ “fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)” NCT03836261 ↗ “Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.” NCT07066995 ↗ “metformin combined with docetaxel, epirubicin, and cyclophosphamide (TEC)” PMID 36525180 ↗ Dec 2022 “in combination with Doxorubicin 60 mg/m2 plus Cyclophosphamide 600 mg/m2” NCT06175390 ↗ “Cyclophosphamide and topotecan are both FDA-approved chemotherapy drugs.” NCT02298348 ↗ “Patients will receive Fludarabine and Cyclophosphamide for conditioning.” NCT06614270 ↗ “pre-transplant, Cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5)” NCT06646497 ↗ “Regimen A:CODOX-M:cyclophosphamide,epirubicin,vincristine,methotrexate.” NCT03558412 ↗ “Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4.” NCT01860170 ↗ “* Doxorubicin(60mg/m2), cyclophosphamide (600mg/m2) D1 X 4cycles 3weeks” NCT03881878 ↗ “supplemented with Cyclophosphamide 50 mg twice a day every second week” NCT00978913 ↗ “post-induction therapy with cyclophosphamide + bortezomib + prednisone” NCT00570180 ↗ “Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days)” NCT07195799 ↗ “(Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel” NCT02483767 ↗ “Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle;” NCT06639672 ↗ “Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle” NCT02244125 ↗ “Drug: Cyclophosphamide Cyclophosphamide is used for lymphodepletion” NCT04844086 ↗ “high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor” NCT05375435 ↗ “C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks” NCT00391066 ↗ “Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.” NCT04611126 ↗ “Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone” NCT06549595 ↗ “maintenance chemotherapy (low-dose cyclophosphamide and vinorelbine)” PMID 35709412 ↗ Jun 2022 “Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle” NCT06627712 ↗ “C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks” NCT00801060 ↗ “3. Cyclophosphamide: 750m/m2 intravenously on days 1 of every cycle;” NCT06918015 ↗ “Cyclophosphamide 600 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles.” NCT06908668 ↗ “Cyclophosphamide 5 mg/kg orally or IV daily on days -11 through -4.” NCT05470491 ↗ “cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4” NCT03793517 ↗ “cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4” NCT03799224 ↗ “AC+H (anthracycline plus cyclophosphamide plus trastuzumab) regimen” NCT07239271 ↗ “200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion.” NCT02317471 ↗ “Cisplatin or anthraxyline and cyclophosphamide (AC) administered IV” NCT07169851 ↗ “Cyclophosphamide: 750 mg/m² , intravenous drip, Day 2 of each cycle” NCT07499271 ↗ “* cyclophosphamide (C): 250 mg/m² orally, D2 to D4 - cycles 1 to 6.” NCT04010968 ↗ “pretreated with cyclophosphamide 250\~500 mg/m2( body surface area)” NCT05605197 ↗ “Cyclophosphamide at 300 mg/m²/day plus Fludarabine at 30 mg/m²/day.” NCT07617285 ↗ “Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)” NCT00203372 ↗ “Treatment by study drug Cyclophosphamide (Endoxan) in combination.” NCT05006664 ↗ “Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1” NCT00930891 ↗ “Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone” NCT02890602 ↗ “Cyclophosphamide will be administered at dose of 20mg/kg for 1 day” NCT04627740 ↗ “Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly.” NCT00664599 ↗ “Cyclophosphamide 600-830 mg/m2 day 1 every 14/21 days for 4 cycles” NCT05296746 ↗ “Drug:cyclophosphamide:300mg/m2 q12h, d1-3, IV,used in cycle 2,4,6” NCT02042690 ↗ “IV cyclophosphamide 0.7mg/m2 every month and placebo tablet daily” NCT05432531 ↗ “fludarabine 25 mg/m2/dose Day -2: cyclophosphamide 900 mg/m2/dose” NCT04815356 ↗ “Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone” NCT07398638 ↗ “Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone” NCT06517511 ↗ “Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone” NCT06647940 ↗ “Oral cyclophosphamide will be given for 30 days in month 2, 4, 6.” NCT06781944 ↗ “Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone” NCT03995147 ↗ “FC regimen (fludarabine and cyclophosphamide) for lymphodepletion” NCT07003568 ↗ “Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w” NCT06102824 ↗ “CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone” NCT00974324 ↗ “Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF” NCT01046825 ↗ “Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days” NCT01564056 ↗ “CHOP : Cyclophosphamide, Doxorubicin, Vincristine, \& Prednisone” NCT02594267 ↗ “intravenous cyclophosphamide (CTX) 1.8 g/m2/d from days -3 to -2” NCT06673459 ↗ “Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2” NCT01751997 ↗ “Cyclophosphamide: 50 mg orally, once daily, every 3 weeks (q3w).” NCT06839560 ↗ “Fludarabine/cyclophosphamide/total body irradiation (Flu/Cy/TBI)” NCT06859424 ↗ “Intravenous cyclophosphamide 7.5-10mg/kg.d\*2 days(Max.500mg/d)” NCT05969522 ↗ “Epirubicin (90mg/m2)+ cyclophosphamide (600mg/m2) 1/14d×4 cycle” NCT05871918 ↗ “cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days” NCT05114720 ↗ “a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide)” NCT00785122 ↗ “fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day” NCT06768151 ↗ “Rituximab Doxorubicin Vincristine Cyclophosphamide Prednisolone” NCT01843868 ↗ “Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate” NCT03917797 ↗ “dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine” NCT01516593 ↗ “Cyclophosphamide, Vindcristine IV, and Prednisone daily orally” NCT04745832 ↗ “Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.” NCT03601624 ↗ “Cyclophosphamide (CTX) 750mg / m2 intravenous infusion, day 1;” NCT05075460 ↗ “CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)” NCT03631862 ↗ “Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles” NCT00824265 ↗ “Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours” NCT00520130 ↗ “Cyclophosphamide: 750 mg/m², intravenous administration, Day 2” NCT07680933 ↗ “Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;” NCT04447573 ↗ “actinomycin D/cyclophosphamide, vincristine, alternate weekly” NCT05139095 ↗ “CIV chemotherapy (cyclophosphamide +Irinotecan + vinorelbine)” NCT06816771 ↗ “Rituximab,Cyclophosphamide,Doxorubicin,Vincristine,Prednisone” NCT04058470 ↗ “Cyclophosphamide 300 mg x1; dexamethasone x 7; vincristine x1” NCT05253495 ↗ “patients will be treated with cyclophosphamide or fludarabine” NCT03941626 ↗ “plus cyclophosphamide IV (250 mg/m2/day for 3 days) (flu/cy)” NCT05727683 ↗ “C, Cyclophosphamide: 300 mg/m2 IV over 30 min (day 1, 8, 15)” NCT04348006 ↗ “R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg/m2 d1” NCT05164770 ↗ “Cyclophosphamide (600 mg/m2), intravenously, every 21 days.” NCT04255056 ↗ “cyclophosphamide. doxorubicin, vincristine , and prednisone” NCT04243434 ↗ “Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)” NCT03035422 ↗ “Cyclophosphamide, doxorubicin, vincristine, and prednisone” NCT02670317 ↗ “Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin” NCT00562913 ↗ “chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1)” NCT03129828 ↗ “cyclophosphamide-methotrexate-5-fluorouracil (CMF) therapy” PMID 23490655 ↗ Mar 2013 “Cyclophosphamide 500mg/m2 IV on D1 (C1-4), 1cycle=21days)” NCT03808480 ↗ “Fludarabine and cyclophosphamide as per standard of care.” NCT05020015 ↗ “Cyclophosphamide 40 mg/kg will be given as an IV infusion” NCT07493538 ↗ “Cyclophosphamide1250 mg/m2/ev/die 1° Vincristine1,4 mg/m2” NCT00795613 ↗ “Cyclophosphamide injection: 650mg/m2, IV infusion, day 1” NCT02800447 ↗ “Drug: Cyclophosphamide; chemotherapy for lymphodepletion” NCT05001451 ↗ “Intravenous infusion of cyclophosphamide and fludarabine” NCT07388277 ↗ “Intravenous Infusion of Cyclophosphamide and Fludarabine” NCT07406724 ↗ “Conditioning: Cyclophosphamide (CY) 50 mg/kg x1 (day -6)” NCT05884333 ↗ “* Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5” NCT00849147 ↗ “cyclophosphamide 1200 mg/m² intravenously on day 1 (d1)” NCT00869284 ↗ “Cyclophosphamide,Liposome doxorubicin and Dexamethasone” NCT02336386 ↗ “Cyclophosphamide 400 mg/m²/day for 4 days (J-12 to J-9)” NCT03079089 ↗ “Drug: Cyclophosphamide 750 mg/m2 i.v. for once (Day -5)” NCT05211557 ↗ “Cyclophosphamide 250 or 300 mg/day on day -5, -4 and -3” NCT04014894 ↗ “Cyclophosphamide 1 g/m\^2 by vein, Over 1 Hour x 2 Days” NCT00500890 ↗ “cyclophosphamide, doxorubicin, vincristine, prednisone” NCT01459887 ↗ “Cyclophosphamide 500 mg/m\^2 IV on Days -5, -4, and -3” NCT06185751 ↗ “Cyclophosphamide, doxorubicin, vincristine, prednisone” NCT05963347 ↗ “Cyclophosphamide: 40 - 50mg/kg/d, from -7d to -6d (2d)” NCT07276737 ↗ “lymphodepletion with cyclophosphamide (300mg/m²/d ×3d)” NCT07441291 ↗ “cyclophosphamide treatment at dose 250mg/m2 for 3 days” NCT04260945 ↗ “cyclophosphamide treatment at dose 250mg/m2 for 3 days” NCT04260932 ↗ “lymphodepletion Drug: Fludarabine and Cyclophosphamide” NCT07108140 ↗ “Cyclophosphamide:IV infusion,600 mg/m2,q3w(13-24 week)” NCT07101614 ↗ “Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2” NCT02084563 ↗ “Drug: Cyclophosphamide (200mg/m2, orally, on days 1-5)” NCT01868828 ↗ “Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Q 4 weeks” NCT01898117 ↗ “cyclophosphamide treatment at dose 250mg/m2 for 3 days” NCT03952923 ↗ “and cyclophosphamide (3×30 mg/m\^2) IV on days -5 to-3” NCT03890198 ↗ “Cyclophosphamide (C), intravenous infusion, 1200mg/m2” NCT07355855 ↗ “Cyclophosphamide: 50 mg per os, daily, for two months” NCT05462613 ↗ “5-fluorouracil, epirubicin and cyclophosphamide [FEC]” PMID 29223479 ↗ Dec 2017 “intravenous cyclophosphamide (300 mg/m2/d for 3 days)” NCT00603460 ↗ “preconditioning with fludarabine and cyclophosphamide” NCT06359041 ↗ “cyclophosphamide 50 mg/kg/d intravenously on days 1-4” NCT00005778 ↗ “cyclophosphamide (500 mg orally on days 1, 8, and 15)” PMID 36529145 ↗ Dec 2022 “Prednisone, Cyclophosphamide, Etoposide, Procarbazine” NCT00151281 ↗ “FC (F, Fludarabine, C, Cyclophosphamide) chemotherapy” NCT05645601 ↗ “Cyclophosphamide(CTX) orally was 100mg/ d for 1 month” NCT03466801 ↗ “Cyclophosphamide, IV infusion for 15 minutes on day 5” NCT02700022 ↗ “Cyclophosphamide, 250 mg/m2 will be given on Day -2.” NCT02579005 ↗ “IV cyclophosphamide (300 mg/m2 on days 1, 8, 15, 22)” NCT04991103 ↗ “Part A: cyclophosphamide, vincristine, dexamethasone” NCT07294677 ↗ “Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle” NCT02867566 ↗ “Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle” NCT02772822 ↗ “Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle” NCT03650933 ↗ “Taxol, Epirubincin, with or without Cyclophosphamide” NCT02842099 ↗ “Cyclophosphamide 500 mg/m² by i.v. bolus or infusion” NCT00256360 ↗ “Cyclophosphamide 300mg/m2 every 12 hours on days 3-5” NCT01184885 ↗ “cyclophosphamide 750 mg/m2 intravenously (IV) day 1” NCT00970385 ↗ “Cyclophosphamide 50 mg/kg IV over 2 hours on day -6” NCT02991898 ↗ “Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4” NCT02395822 ↗ “Cyclophosphamide: 50 mg per os, daily, for 6 months” NCT06425133 ↗ “Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)” NCT06468683 ↗ “Cyclophosphamide 80 mg/kg/course on the days +3, +4” NCT06475820 ↗ “Cyclophosphamide 500mg/m2 by i.v bolus or infusion.” NCT00286819 ↗ “Cyclophosphamide, Fludarabine, Interleukin-2, Mesna” NCT00640796 ↗ “Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4” NCT01385423 ↗ “cyclophosphamide(C), 750mg/m2 for injection on day1” NCT01788137 ↗ “cyclophosphamide (750 mg/m2 intravenously on day 1)” NCT06739265 ↗ “Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4” NCT03081780 ↗ “post-transplant cyclophosphamide 50 mg/kg on Day +3” NCT07570745 ↗ “Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4” NCT03050216 ↗ “750 mg/m2 intravenous on day 5 for cyclophosphamide” PMID 37011643 ↗ Mar 2023 “cyclophosphamide (Cy) (1.8 g/m2/kg, days -5 and -4)” NCT06984536 ↗ “Cyclophosphamide : 60 mg/m² daily on days -3 to -2” NCT01015742 ↗ “Cyclophosphamide 600mg/m 2, ivgtt, d1 Q3w, 4 cycle” NCT05400993 ↗ “Cyclophosphamide 400 mg/2, Continuous infusion 1-4” NCT00113919 ↗ “Drug: Cyclophosphamide， Administered intravenously” NCT05613348 ↗ “Cyclophosphamide (IV, 50 mg/kg on days -3 and -2)” NCT00336843 ↗ “Cyclophosphamide 500 mg/m2, once daily for 3 days” NCT05930314 ↗ “* Cyclophosphamide 750 mg/m\^2 on Days -5, -4, -3” NCT00912223 ↗ “Epirubicin/Cyclophosphamide Followed by Docetaxel” NCT03507465 ↗ “Cyclophosphamide 750 mg/m2 IV Day 8 of each Cycle” NCT01139359 ↗ “Cyclophosphamide Chemotherapy for lymphodepletion” NCT05722418 ↗ “cyclophosphamide 500 mg/m2/d infused over 1 hour” NCT00580034 ↗ “Cyclophosphamide 600 mg/m2 (AC) for four courses” PMID 41034674 ↗ Oct 2025 “cyclophosphamide 500 mg/m2/d infused over 1 hour” NCT00578942 ↗ “Cyclophosphamide: 600 mg/m², day 1, 21-day cycle” NCT07342283 ↗ “Cyclophosphamide IV (60 mg/kg/day) day-3 & day-2” NCT00863460 ↗ “Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6” NCT04332822 ↗ “Cyclophosphamide iv 750 mg/m2 over 15-45 minutes” NCT00440583 ↗ “Cyclophosphamide 200 mg/m2/day IV 1 h 1 - 5 days” NCT02842931 ↗ “cyclophosphamide 300mg/m2 for 3 consecutive days” NCT05315778 ↗ “cyclophosphamide 1.8 g/ m²/day on days -3 and -2” NCT07575412 ↗ “low-dose cyclophosphamide (5 mg/kg) orally daily” NCT03922724 ↗ “cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4” NCT01461837 ↗ “cyclophosphamide 1200 mg/m(2)/day IV for 4 days” NCT00973804 ↗ “Drug: Cyclophosphamide: 300 mg/ m\^2 (D-5\~D-3)” NCT06206902 ↗ “Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5” NCT01597778 ↗ “cyclophosphamide 1.8 g/m²/day on days -3 and -2” NCT07562568 ↗ “plus cyclophosphamide (600 mg per square meter)” NCT06831955 ↗ “2. cyclophosphamide: 400mg/m2 D1-4, intravenous” NCT04065308 ↗ “Cyclophosphamide, 500-750 mg/m², ivgtt, day 2;” NCT05428670 ↗ “Cyclophosphamide: 1000 mg/m2 iv on days 35, 59” NCT02396043 ↗ “oral cyclophosphamide (CTX) daily on days 1-14” NCT00024102 ↗ “cyclophosphamide (1.8 g/m2/day, days -5 to -4)” NCT04582604 ↗ “Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6,-5” NCT05298358 ↗ “Cyclophosphamide (CTX): 500 mg/m², days 7, 21.” NCT07059156 ↗ “doxorubicin (Adriamycin)/cyclophosphamide (AC)” NCT03473691 ↗ “cyclophosphamide (1.0 g/m2/day, days -5 to -4)” NCT07677306 ↗ “Cyclophosphamide iv: 50 mg/kg iv over 2 hours” NCT02676622 ↗ “Fludarabine and cyclophosphamide IV infusion.” NCT06377228 ↗ “cyclophosphamide 1.8g/m²/day on day -4 to -3.” NCT03256071 ↗ “modified BUCY (busulfan and cyclophosphamide)” NCT05823714 ↗ “modified BUCY (busulfan and cyclophosphamide)” NCT05809167 ↗ “Cyclophosphamide 300 mg/m\^2 - intravenously.” NCT03381183 ↗ “Cyclophosphamide 50mg orally, once daily, Q3W” NCT06771609 ↗ “fludarabine, thiotepa ,cyclophosphamide (FTC)” NCT04121507 ↗ “FC regimen (fludarabine and cyclophosphamide)” NCT07003555 ↗ “Cyclophosphamide,750mg／㎡,d2,intravenous drip” NCT06412068 ↗ “Doxorubicin + cyclophosphamide (combination)” NCT05774886 ↗ “B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip” NCT05572983 ↗ “Endoxan(R), Cyclostin(R) = Cyclophosphamide” NCT00991211 ↗ “Cyclophosphamide: 750 mg/m2/day IV on day 5” NCT04992377 ↗ “Cyclophosphamide 1.0g/m\^2/d qd IVD d-5\~-2” NCT03629873 ↗ “Cyclophosphamide 500 mg/m2 as an i.v. bolus” NCT00544765 ↗ “Cyclophosphamide (C) 800 mg/m2 IV over 1 hr” NCT01858922 ↗ “cyclophosphamide (60 mg/kg/day x2 days IV)” NCT00604136 ↗ “FC regimen: Fludarabine + Cyclophosphamide” NCT07399769 ↗ “Cyclophosphamide, PO, 25mg/m² continuously” NCT03011528 ↗ “Day 1-5: Cyclophosphamide 100 mg/m2 BID PO” NCT05099471 ↗ “FC regimen: Fludarabine + Cyclophosphamide” NCT07508605 ↗ “a dose of 50mg/kg/d cyclophosphamide (CTX)” NCT03689465 ↗ “FC regimen: Fludarabine + Cyclophosphamide” NCT07097207 ↗ “topotecan, cyclophosphamide, and etoposide” NCT03042429 ↗ “FC regimen: Fludarabine + Cyclophosphamide” NCT07584889 ↗ “Drug: Cyclophosphamide 600 mg/m² given IV” NCT03799679 ↗ “plus Cyclophosphamide 500mg/m2 IV on Day1” NCT03576378 ↗ “cyclophosphamide: 400 mg/m\^2 IV days 1-5” NCT01576692 ↗ “Epirubicine, Cyclophosphamide, Paclitaxel” NCT03515798 ↗ “Cyclophosphamide (CTX) 400 mg/m2/d, d2, 5” NCT06447090 ↗ “Cyclophosphamide: 750mg/m2, iv or ivd, D1” NCT05093140 ↗ “Cyclophosphamide (400 mg/sm, D 1-5)/cycle” NCT00842114 ↗ “PO cyclophosphamide 400mg on D1, 8 and 15” NCT03143049 ↗ “Cyclophosphamide - 750 mg/m2 - IV - Day 1” NCT01839097 ↗ “C（Cyclophosphamide）： CTX 250mg /m2·d，d1-3” NCT03980002 ↗ “Cyclophosphamide 50 mg/kg i.v. day +3+4.” NCT03434704 ↗ “intravenous cyclophosphamide 750 mg/m(2)” PMID 26687958 ↗ Mar 2015 “Cyclophosphamide 30 mg/kg IV over 30 min” NCT00042367 ↗ “(e.g., fludarabine and cyclophosphamide)” NCT07480213 ↗ “Cyclophosphamide 600-800mg/m2 for 2 days” NCT03664661 ↗ “Drug: Fludarabine Drug: Cyclophosphamide” NCT04230473 ↗ “cyclophosphamide (60mg/m2 days -6 \& -5)” NCT00676806 ↗ “Cyclophosphamide: 750 mg/m2 IV on day 1” NCT03542266 ↗ “C: cyclophosphamide 500 mg/m², IV. Q3W.” NCT07410234 ↗ “Cyclophosphamide: 750 mg/m2 IV on day 3” NCT00401817 ↗ “Drug: Cyclophosphamide Cyclophosphamide” NCT06486337 ↗ “Cyclophosphamide 250mg/ m2/day x 3 days” NCT05831033 ↗ “* Cyclophosphamide i.v.: 400 mg/m² (D1)” NCT05820841 ↗ “Day-5# Cyclophosphamide 1.8 g/m2/day CI” NCT05088226 ↗ “Drug: Fludarabine and Cyclophosphamide.” NCT07487597 ↗ “* Cyclophosphamide 750 mg/m2 i.v. day 1” NCT00466258 ↗ “Cyclophosphamide 750 mg/m\^2 IVPB Day 1” NCT02633137 ↗ “mobilisation with 2x1g Cyclophosphamide” NCT01895244 ↗ “cyclophosphamide 600 mg/m² on Day 1 q3w” NCT06876636 ↗ “CHOP : cyclophosphamide 750 mg/m2 IV D1” NCT06890585 ↗ “Drug: cyclophosphamide 250 mg/m\^2 d1-3” NCT03170141 ↗ “followed by epirubicin-cyclophosphamide” NCT06977542 ↗ “Drug 1: Fludarabine + Cyclophosphamide” NCT06358053 ↗ “cyclophosphamide [Endoxan] 50 mg daily” NCT04604028 ↗ “cyclophosphamide (750mg/m2) on days -5” NCT05744037 ↗ “Cyclophosphamide 1250 mg/m2 i.v. day 1” NCT00433433 ↗ “Cyclophosphamide 1200mg/m2 on Day 1 IV” NCT01304849 ↗ “cyclophosphamide (start dose 600mg/m2)” NCT00798070 ↗ “Cyclophosphamide 750mg/m2, i.v., Day 1” NCT03151044 ↗ “Drug: Fludarabine and Cyclophosphamide” NCT07123493 ↗ “and cyclophosphamide (250 mg/m\^2 i.v.” NCT02445248 ↗ “Cyclophosphamide: 750mg/m2 iv.drip D1;” NCT05577364 ↗ “Cyclophosphamide 25 mg/kg iv x 2 days” NCT04943757 ↗ “* Cyclophosphamide 600 mg/m2 Days 1-4” NCT00577512 ↗ “Cyclophosphamide 750 mg/m² i.v. day 1” NCT00064116 ↗ “Cyclophosphamide at 750mg/m2 on day 1” NCT06290817 ↗ “Cyclophosphamide: 750 mg/m2 i.v. day1” NCT00791947 ↗ “High dose etoposide, Cyclophosphamide” NCT00460421 ↗ “Cyclophosphamide:15-35 mg/kg/d，QD×2D” NCT05438797 ↗ “Cyclophosphamide 750 mg/ms iv day +1” NCT02223208 ↗ “cyclophosphamide 750mg/m2 d1、8 ivgtt” NCT03513601 ↗ “Cyclophosphamide (CTX350mg/㎡ d2, d5)” NCT06529250 ↗ “Cyclophosphamide 750 mg/m², iv Day 1” NCT07494565 ↗ “Drug: Fludarabine + Cyclophosphamide” NCT07139067 ↗ “Cyclophosphamide 750 mg/m2/day IV d5” NCT01818908 ↗ “Cyclophosphamide：750 mg/m2，ivgtt，D1；” NCT02526823 ↗ “Cyclophosphamide: 750 mg/m² day 1 iv” NCT02063685 ↗ “cyclophosphamide (750 mg/㎡ on day 1)” NCT06959732 ↗ “Cyclophosphamide 50 mg/d, po, d1-d21” NCT02897050 ↗ “Cyclophosphamide (300mg/m2 per day)” NCT06010472 ↗ “Cyclophosphamide (C) 750mg/m2 IV d1” NCT06158399 ↗ “Cyclophosphamide 750 mg/m2 D1, I.V.” NCT06255704 ↗ “Cyclophosphamide 750 mg/m²,iv, day1” NCT00946374 ↗ “Cyclophosphamide 750 mg/m2 D1, I.V.” NCT04736914 ↗ “Cyclophosphamide 750mg/m2, ivgtt D1” NCT05018520 ↗ “CTX (cyclophosphamide) 25mg/kg/dx4d” NCT03821987 ↗ “cyclophosphamide 400mg/m2 ivgtt d2;” NCT05809180 ↗ “Cyclophosphamide 750mg/m2, ivgtt D1” NCT04480099 ↗ “cyclophosphamide at 3 g/m2 on day 8” NCT00148317 ↗ “cyclophosphamide 50 mg/kg x 2 doses” NCT01370213 ↗ “Cyclophosphamide 750mg/ m2 IV day 1” NCT00530179 ↗ “Cyclophosphamide 300 mg / m\^2 i.v.” NCT04206943 ↗ “cyclophosphamide 25-30mg / kg / d-5” NCT06769568 ↗ “Cyclophosphamide, 10 mg/Kg iv day 1” NCT00461747 ↗ “Drug: Cyclophosphamide,Fludarabine;” NCT05206071 ↗ “Cyclophosphamide 750 mg/m2 i.v. d 1” NCT00517894 ↗ “abbreviation： CTX： cyclophosphamide” NCT03201471 ↗ “cyclophosphamide 400 mg/m2 days 1-4” NCT00670631 ↗ “Cyclophosphamide: 750 mg/m2, IV, d1” NCT07059650 ↗ “* Cyclophosphamide 750 mg / m\^2，D2” NCT05257018 ↗ “cyclophosphamide (500mg/m2, 1d Q3W)” NCT05558722 ↗ “Cyclophosphamide 500, every 3 weeks” NCT02001506 ↗ “Drug: Cyclophosphamide,Fludarabine” NCT04938115 ↗ “Drug: Cyclophosphamide,Fludarabine” NCT04792593 ↗ “Day -7 Cyclophosphamide at 60mg/kg” NCT02409576 ↗ “Cyclophosphamide (600 mg/m2) iv D1” NCT05909332 ↗ “Cyclophosphamide 300mg/m2.d d1to 3” NCT04599452 ↗ “Cyclophosphamide 300mg/m2.d d1to 3” NCT04599426 ↗ “Drug: Cyclophosphamide,Fludarabine” NCT04546906 ↗ “Drug: Cyclophosphamide,Fludarabine” NCT04546893 ↗ “cyclophosphamide 750mg/m2 IV day 1” NCT00854568 ↗ “cyclophosphamide 750mg/m2 IV day 1” NCT01804127 ↗ “cyclophosphamide, 750mg/m² IV day1” NCT02445404 ↗ “Cyclophosphamide: 750mg/m2, IV, d1” NCT05238064 ↗ “cyclophosphamide 750mg/m2 IV day 5” NCT01914718 ↗ “Cyclophosphamide 500 mg/㎡ iv day 1” NCT01917578 ↗ “Drug: Cyclophosphamide,Fludarabine” NCT05618041 ↗ “cyclophosphamide(1.2g/m2.d, d3-d4)” NCT06933394 ↗ “Cyclophosphamide: 750 mg/m², Day 1” NCT07677813 ↗ “Cyclophosphamide: 750mg/m2, IV, d1” NCT07032532 ↗ “cyclophosphamide (50mg/kg/day IV)” NCT03128996 ↗ “cyclophosphamide and/or topotecan” NCT03236857 ↗ “Cyclophosphamide intravenous drip” NCT06760039 ↗ “cyclophosphamide (600mg/m² i.v.d1” NCT03201861 ↗ “cyclophosphamide 750 mg/m2 iv D2” NCT03318835 ↗ “fludarabine and cyclophosphamide” NCT04727151 ↗ “Cyclophosphamide 750mg/m2 day +1” NCT01679860 ↗ “Cyclophosphamide and Fludarabine” NCT06630611 ↗ “iv Cyclophosphamide (60 mg/kg/d)” NCT06758726 ↗ “cyclophosphamide 750 mg/m2 iv D2” NCT04164368 ↗ “cyclophosphamide 300mg/m2/d×3day” NCT06945523 ↗ “fludarabine and cyclophosphamide” NCT06947460 ↗ “cyclophosphamide 300mg/m2/d×3day” NCT06992583 ↗ “oral metronomic cyclophosphamide” NCT03879512 ↗ “Cyclophosphamide: 750 mg/m2, d1” NCT05974085 ↗ “cyclophosphamide 750 mg/m2 day1” NCT06347653 ↗ “Cyclophosphamide 10 mg/kg day 1” NCT00560053 ↗ “Cyclophosphamide (500 mg/m2 iv)” NCT01433562 ↗ “Drug: Low dose cyclophosphamide” NCT06471673 ↗ “Cyclophosphamide 500 mg/m² i.v.” NCT00847444 ↗ “Cyclophosphamide 50 mg PO daily” NCT07130032 ↗ “cyclophosphamide 500 mg/m\^2 IV” NCT00262067 ↗ “Cyclophosphamide 750mg/ ｍ２ , d５” NCT04134247 ↗ “Cyclophosphamide 500 mg/m² i.v.” NCT00670878 ↗ “cyclophosphamide: 750 mg/m2, D1” NCT06901999 ↗ “Day +3 to +4: Cyclophosphamide” NCT03314974 ↗ “docetaxel and cyclophosphamide” NCT04836156 ↗ “Cyclophosphamide 250 mg/m² Q3W” NCT04980859 ↗ “Cyclophosphamide 750mg/ m2, D1” NCT05040555 ↗ “* Cyclophosphamide (750 mg/m2)” NCT02605694 ↗ “Cyclophosphamide (50 mg/m2，d1)” NCT06569485 ↗ “Cyclophosphamide， 750mg/m² ，D1” NCT05527912 ↗ “fludarabine + cyclophosphamide” NCT07510828 ↗ “Cyclophosphamide 750mg / m2 d1” NCT04152577 ↗ “Cytoxan(R) (cyclophosphamide)” NCT00602667 ↗ “Cyclophosphamide-750 mg/m2:D1” NCT01285765 ↗ “Cyclophosphamide 200 mg/kg iv” NCT01238328 ↗ “Preop chemo: cyclophosphamide” NCT02018458 ↗ “Cyclophosphamide 750mg /m2 d1” NCT05097443 ↗ “Cyclophosphamide 750 mg/m2 D2” NCT06750991 ↗ “cyclophosphamide 750 mg/m² IV” NCT07706959 ↗ “cyclophosphamide: 750mg/m2 d1” NCT05290090 ↗ “Cyclophosphamide 750mg/m2 D2” NCT06701357 ↗ “Cyclophosphamide 750mg/m2 d1” NCT05230680 ↗ “cyclophosphamide (500 mg/m2)” NCT01996267 ↗ “Cyclophosphamide: 750 mg/m2” NCT05896813 ↗ “Cyclophosphamide (Cytoxan®)” NCT02128230 ↗ “Cyclophosphamide (Cytoxan®)” NCT07486089 ↗ “cyclophosphamide :600 mg/m2” NCT01150513 ↗ “Cyclophosphamide 750mg/m2 1” NCT00504491 ↗ “IV cyclophosphamide 200 mg” NCT01543152 ↗ “Cyclophosphamide injection” NCT04715217 ↗ “Cyclophosphamide injection” NCT04714827 ↗ “Cyclophosphamide injection” NCT04714593 ↗ “cyclophosphamide (Cytoxan)” NCT00132691 ↗ “* Cyclophosphamide * Mesna” NCT00801580 ↗ “Cyclophosphamide 500 mg/m²” NCT02339532 ↗ “cyclophosphamide 750 mg/m²” NCT04263584 ↗ “cyclophosphamide, 4 cycles” NCT01206881 ↗ “cyclophosphamide (CTX) IV” NCT00003815 ↗ “Cyclophosphamide, Cytoxan” NCT02981524 ↗ “cyclophosphamide 50mg/kg” NCT06378060 ↗ “* Cyclophosphamide (Cy)” NCT02988466 ↗ “Drugs: Cyclophosphamide” NCT05667506 ↗ “Cyclophosphamide 600 mg” NCT02527746 ↗ “Drug: Cyclophosphamide” NCT05947487 ↗ “Drug: Cyclophosphamide” NCT05491694 ↗ “Drug: Cyclophosphamide” NCT04684147 ↗ “Drug: Cyclophosphamide” NCT06470633 ↗ “Drug: Cyclophosphamide” NCT04586478 ↗ “Drug: Cyclophosphamide” NCT04440436 ↗ “Drug: Cyclophosphamide” NCT05326243 ↗ “Drug: Cyclophosphamide” NCT04232826 ↗ “Drug: Cyclophosphamide” NCT03206671 ↗ “Drug: Cyclophosphamide” NCT06852573 ↗ “Drug: Cyclophosphamide” NCT00493870 ↗ “CTX, cyclophosphamide” NCT06227117 ↗ “(-)-Cyclophosphamide” NCT02220985 ↗ “C: Cyclophosphamide.” NCT07378306 ↗ “* Cyclophosphamide” NCT02179359 ↗ “* Cyclophosphamide” NCT00167219 ↗ “Cyclophosphamide” NCT06316076 ↗ “Cyclophosphamide” NCT00798070 ↗ “cyclophosphamide” NCT06705127 ↗ “Cyclophosphamide” NCT04348006 ↗ “Cyclophosphamide” NCT01145976 ↗ “Cyclophosphamide” NCT03971045 ↗ “Cyclophosphamide” NCT02665065 ↗ “Cyclophosphamide” NCT05421897 ↗ “Cyclophosphamide” NCT00592111 ↗ “Cyclophosphamide” NCT06193889 ↗ “Cyclophosphamide” NCT03571308 ↗ “Cyclophosphamide” NCT05938725 ↗ “Cyclophosphamide” NCT06342960 ↗ “Cyclophosphamide” NCT06371807 ↗ “cyclophosphamide” NCT00190671 ↗ “Cyclophosphamide” NCT06400303 ↗ “Cyclophosphamide” NCT05515185 ↗ “Cyclophosphamide” NCT04498793 ↗ “Cyclophosphamide” NCT06588491 ↗ “Cyclophosphamide” NCT06626919 ↗ “Cyclophosphamide” NCT03647423 ↗ “Cyclophosphamide” NCT03648697 ↗ “Cyclophosphamide” NCT02191930 ↗ “Cyclophosphamide” NCT03837873 ↗ “Cyclophosphamide” NCT05207514 ↗ “Cyclophosphamide” NCT01873807 ↗ “Cyclophosphamide” NCT00734877 ↗ |
| Known as | AB-101 | “AlloNK® (also known as AB-101) is a non-genetically modified, allogeneic, off-the-shelf, cryopreserved cord blood-derived NK cell therapy.” NCT06991114 ↗ |
| Known as | allogeneic | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02496390 ↗ |
| Known as | AlloNK | “AlloNK® (also known as AB-101) is a non-genetically modified, allogeneic, off-the-shelf, cryopreserved cord blood-derived NK cell therapy.” NCT06991114 ↗ |
| Known as | B-518 | “B-518” NCT03670966 ↗ |
| Known as | CAR2219 CAR-T cells | “This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.” NCT06834529 ↗ |
| Known as | CAR2219-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06834529 ↗ |
| Known as | CB-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05722418 ↗ |
| Known as | CB-012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06128044 ↗ |
| Known as | CD19-CAR-DNT cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05453669 ↗ |
| Known as | CD19CD22 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06078306 ↗ |
| Known as | CFM | “Cyclophosphamide (CFM): 1000 mg/m2, i.v., day 22.” NCT00526175 ↗ |
| Known as | Ciclofosfamide | “Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,” NCT00774826 ↗ |
| Known as | Conditioning chemotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02356159 ↗ |
| Known as | Conditioning regimen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01238328 ↗ |
| Known as | CPA | “cyclophosphamide (CPA)” NCT01507103 ↗1“Cyclophosphamide (CPA)” NCT02049151 ↗ |
| Known as | CPH | “Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg)” NCT00976300 ↗ |
| Known as | CPM | “Nephritis is the most severe manifestation of lupus. Between 1950s and 1970s, corticosteroids were used for the treatment of lupus nephritis (LN) ,and using of...” NCT04424602 ↗6“Open-label studies suggested efficacy of monthly IV cyclophosphamide (CPM) without induction for delaying progression but no randomized trial was conducted so far.” PMID 28045953 ↗ Jan 2017 “104 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX)” NCT03063983 ↗ “additional cyclophosphamide (CPM) on day 10 only in T-ALL patients with prednisone poor-response” NCT01117441 ↗ “cyclophosphamide (CPM) on days 36 and 64” NCT00613457 ↗ “cyclophosphamide (CPM) on days 36 and 64” NCT00430118 ↗ “cyclophosphamide (CPM) IV over 1 hour” NCT00550992 ↗ |
| Known as | CTX | “Iodine-131-labeled Monoclonal Antibody BC8 (anti-CD45), 131I-BC8; plus Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed by Allogeneic Bone Marrow, ABM; with,...” NCT00002554 ↗74“The purpose of this study is to determine the safety of anti-HIV drugs combined with low-dose chemotherapy (consisting of cyclophosphamide [CTX]) in HIV-positive patients.” NCT00000899 ↗ “Participants with persistent proteinuria ≥ 1 g/day after 8 weeks of corticosteroid monotherapy will receive 0.8-1.0 g of intravenous cyclophosphamide (CTX) every 4 weeks” NCT03418779 ↗ “This study is a phase 1/2 study to assess safety and hematologic response rate of Ixazomib (MLN) in combination with Cyclophosphamide (CTX) and Dexamethasone (DEX).” NCT03236792 ↗ “Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed by Allogeneic Bone Marrow, AlBM; with, as indicated, Intrathecal Cytarabine, IT ARA-C, NSC-63878.” NCT00002502 ↗ “prednisolone (PRED) (0.8mg/kg/d) plus Cyclophosphamide (CTX) (1.5-2mg/kg/d) followed by Azathioprine (AZA) (1-1.5mg/kg/d) as induction-maintenance therapy” NCT02954939 ↗ “cyclophosphamide（CTX） 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel（PTX） 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.” NCT03949634 ↗ “an amendment to the trial added two cohorts, both received one dose of cyclophosphamide (CTX) administered 1 week before study treatment initiation” PMID 40187749 ↗ Apr 2025 “Oral administration of cyclophosphamide (CTX) and capecitabine may have a greater potential for treatment of metastatic breast cancer (MBC) due to” PMID 21874317 ↗ Aug 2011 “A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.” NCT01493154 ↗ “Carboplatin, CBDCA, NSC-241240; or CAP: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Cisplatin, CDDP, NSC-119875.” NCT00002477 ↗ “The induction therapy is a combination of Blinatumomab(Blina), Vindesine(VDS), Cyclophosphamide(CTX) and Dexamethasone(DXM).” NCT06742515 ↗ “CAF: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Fluorouracil, 5-FU, NSC-19893; followed by TMX.” NCT00929591 ↗ “conditioning regimen (cyclophosphamide (CTX) and total body irradiation (TBI) vs busulfan (BU) and CTX vs other)” NCT00002989 ↗ “Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX)” NCT07588360 ↗ “CVP: Cyclophosphamide, CTX, NSC-26271; Etoposide, VP-16, NSC-141540; Cisplatin, CDDP, NSC-119875.” NCT00002488 ↗ “the condition with iv-busulfan (iv-BU) and cyclophosphamide (CTX) is feasible with low toxicity” NCT01435447 ↗ “Cyclophosphamide (CTX) is administered as a lymphodepletion regimen prior to NK042 infusion.” NCT06773091 ↗ “single dose of the immunosuppressive agent cyclophosphamide (CTX) to induce immune tolerance” NCT05800041 ↗ “Anti-CD3 Murine Monoclonal Antibody OKT3, MOAB OKT3; with Cyclophosphamide, CTX, NSC-26271” NCT00002482 ↗ “oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle” NCT03971045 ↗ “cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24” NCT00002611 ↗ “patients receive cyclophosphamide (CTX) IV over 30 minutes on days 1, 15, and 29” NCT00002514 ↗ “doxorubicin (DOX) IV and cyclophosphamide (CTX) IV every 3 weeks for 4 courses” NCT00002967 ↗ “Metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs.” PMID 30413837 ↗ Nov 2018 “Cyclophosphamide (CTX) 500 mg/m2/day (divided q12 hrs) IV day 1, 2, 3” NCT00187161 ↗ “intravenous cyclophosphamide (CTX) 1.8 g/m2/d from days -3 to -2” NCT06673459 ↗ “oral cyclophosphamide (CTX) IV on day 1 of weeks 5, 7, and 9” NCT00002531 ↗ “Patients receive cyclophosphamide (CTX) IV on days -3 and -2” NCT00003913 ↗ “cyclophosphamide (CTX) IV over 1 hour on days 1 and 2” NCT00006455 ↗ “Cyclophosphamide(CTX) orally was 100mg/ d for 1 month” NCT03466801 ↗ “CTX (cyclophosphamide) 300 mg/m2 IV short infusion” NCT00187005 ↗ “oral cyclophosphamide (CTX) on days 22-25 (ABCM)” NCT00002653 ↗ “Cyclosphosphamide (CTX) IV is given over 1 hour.” NCT00002788 ↗ “oral cyclophosphamide (CTX) daily on days 1-14” NCT00024102 ↗ “Cyclophosphamide (CTX): 500 mg/m², days 7, 21.” NCT07059156 ↗ “cyclophosphamide (CTX) IV over 1 hour on day 9” NCT00003728 ↗ “Cyclophosphamide (CTX) 1200 mg/m2 IV on D1,15” NCT05660473 ↗ “C: cyclophosphamide (CTX） T: paclitaxel (PTX）” NCT03876886 ↗ “a dose of 50mg/kg/d cyclophosphamide (CTX)” NCT03689465 ↗ “Cyclophosphamide (CTX) 400 mg/m2/d, d2, 5” NCT06447090 ↗ “Cyclophosphamide (CTX350mg/㎡ d2, d5)” NCT06529250 ↗ “CTX (cyclophosphamide) 25mg/kg/dx4d” NCT03821987 ↗ “Cyclophosphamide (CTX) 750mg/ m2 d5” NCT05164770 ↗ “abbreviation： CTX： cyclophosphamide” NCT03201471 ↗ “Cyclophosphamide, CTX, NSC-26271” NCT00002471 ↗ “Cyclophosphamide, CTX, NSC-26271” NCT00002510 ↗ “Cyclophosphamide (CTX, Cytoxan)” NCT01861106 ↗ “CTX Cyclophosphamide, NSC-26271” NCT00002691 ↗ “Cyclophosphamide (CTX, Cytoxan)” NCT00923364 ↗ “CTX Cyclophosphamide, NSC-26271” NCT00002535 ↗ “CTX Cyclophosphamide, NSC-26271” NCT00002565 ↗ “CTX Cyclophosphamide, NSC-26271” NCT00002576 ↗ “CTX Cyclophosphamide, NSC-26271” NCT00002599 ↗ “CTX Cyclophosphamide, NSC-26271” NCT00002757 ↗ “Cyclophosphamide(CTX, Cytoxan)” NCT01176006 ↗ “NSC-3590 CTX Cyclophosphamide” NCT00002704 ↗ “Drug: Cyclophosphamide (CTX)” NCT02566993 ↗ “Drug: Cyclophosphamide (CTX)” NCT06594640 ↗ “Drug: Cyclophosphamide (CTX)” NCT02256150 ↗ “Drug: Cyclophosphamide(CTX)” NCT02532777 ↗ “cyclophosphamide (CTX) IV” NCT00003815 ↗ “cyclophosphamide (CTX) IV” NCT00002700 ↗ “cyclophosphamide (CTX) IV” NCT00002696 ↗ “Cyclophosphamide (CTX)” NCT07120607 ↗ “Cyclophosphamide (CTX)” NCT06809712 ↗ “Cyclophosphamide (CTX)” NCT06809699 ↗ “Cyclophosphamide (CTX)” NCT07131085 ↗ “Cyclophosphamide (CTX)” NCT06802315 ↗ “Cyclophosphamide (CTX)” NCT06854250 ↗ “Cyclophosphamide (CTX)” NCT02257697 ↗ “Cyclophosphamide (CTX)” NCT00002836 ↗ “cyclophosphamide (CTX)” NCT00002701 ↗ “Cyclophosphamide，CTX” NCT06319456 ↗ “CTX Cyclophosphamide” NCT00002630 ↗ |
| Known as | cyc | “In this comparative open-label cohort study, the investigators compared the efficacy and safety of tacrolimus (TAC)and cyclophosphamide (CYC) in the treatment of diffuse...” NCT01207297 ↗12“Scattered research in adults showed that both mycophenolate mofetil (MMF) and cyclophosphamide (CYC) can be used in the induction therapy of lupus nephritis.” NCT05495893 ↗ “Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2” NCT02460588 ↗ “PDN and oral cyclophosphamide (CYC) versus high dose intravenous (iv) CYC versus intermediate dose iv CYC” NCT00336414 ↗ “Mycophenolate might be an alternative therapy to avoid toxicities of cyclophosphamide (CYC).” PMID 26835147 ↗ Jan 2016 “including cyclophosphamide(CYC), methotrexate(MTX) and azathioprine(AZA) etc.” NCT03096275 ↗ “after lymphodepletion with fludarabine (flu) and cyclophosphamide (cyc).” PMID 31110096 ↗ May 2019 “oral azathioprine (AZA) versus intravenous pulse cyclophosphamide (CYC)” PMID 18240234 ↗ Feb 2008 “Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2” NCT06152172 ↗ “limited cyclophosphamide (CYC) exposure” PMID 25693055 ↗ Apr 2015 “Chemotherapy: cyclophosphamide (CYC)” NCT06451159 ↗ “Cyclophosphamide (CYC)” NCT05679401 ↗ “Cyclophosphamide (CYC)” NCT07077486 ↗ |
| Known as | cyclo | “cyclophosphamide (cyclo; 50 mg per day, first 2 weeks in each 4 week cycle)” PMID 32620163 ↗ Jul 2020 |
| Known as | Cyclophosphamid | “Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.” NCT00590447 ↗16“Drug: Cyclophosphamid Lympho-conditioning Agent” NCT06027853 ↗ |
| Known as | Cyclophosphamide (C) | “Cyclophosphamide (C)” NCT01858922 ↗ |
| Known as | Cyclophosphamide (CPA) | “Cyclophosphamide (CPA)” NCT00722098 ↗1“Cyclophosphamide - CPA” NCT00313235 ↗ |
| Known as | cyclophosphamide (CPM) | “cyclophosphamide (CPM)” NCT01707004 ↗ |
| Known as | cyclophosphamide (CTX) | “cyclophosphamide (CTX)” NCT01707004 ↗ |
| Known as | Cyclophosphamide (Cytoxan ) | “Cyclophosphamide (Cytoxan ®)” NCT01860170 ↗6“Cyclophosphamide (Cytoxan®)” NCT02128230 ↗ “Cyclophosphamide (Cytoxan)” NCT01527422 ↗ “Cyclophosphamide - Cytoxan” NCT01001780 ↗ “cyclophosphamide (Cytoxan)” NCT00132691 ↗ “cyclophosphamide: cytoxan” NCT00640796 ↗ “cyclophosphamide,Cytoxan” NCT00085423 ↗ |
| Known as | Cyclophosphamide for Injection | “Cyclophosphamide for Injection” NCT06838832 ↗ |
| Known as | Cyclophosphamide injection | “Cyclophosphamide injection” NCT04714827 ↗ |
| Known as | cyclophosphamide sulfate | “cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24” NCT00002611 ↗ |
| Known as | Cyclophosphamide, Sendoxan, Baxter A/S | “Cyclophosphamide, Sendoxan®, Baxter A/S” NCT00937300 ↗2“Cyclophosphamide, Sendoxan®, Baxter A/S” NCT00937625 ↗ “Cyclophosphamide, Sendoxan®, Baxter A/S” NCT00197912 ↗ |
| Known as | Cyclophosphamide: Endoxan | “Cyclophosphamide: Endoxan” NCT01301040 ↗ |
| Known as | Cytophosphan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01175772 ↗ |
| Known as | cytophosphane | “Cyclophosphamide (CP), also known as cytophosphane among other names, is a chemotherapy agent” NCT04024761 ↗ |
| Known as | Cytoxan | “Patients will be randomized to receive 5 cycles of combination chemotherapy (5-FU, adriamycin, leucovorin, cytoxan, G-CSF) either as initial therapy (preoperative) or...” NCT00001250 ↗58“The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg) the next day.” NCT03914768 ↗ “After the busulfan treatment, you will receive 4 doses each of two drugs, cyclophosphamide (also known as Cytoxan) and fludarabine, over 2 hours into your vein.” NCT00281879 ↗ “A Phase II Trial With VELCADE® (PS-341), Cytoxan (Cyclophosphamide), Dexamethasone and Thalomid® (VEL-CTD) in Previously Untreated Multiple Myeloma Patients” NCT00438841 ↗ “Combination chemotherapy consists of Flurouricil, Leucovorin, Adriamycin, and Cytoxan (FLAC) which will be given every 21 days for 10 cycles.” NCT00001239 ↗ “Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM.” NCT06072612 ↗ “Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC.” NCT00394251 ↗ “intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (Cytoxan)” NCT00256243 ↗ “FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF” NCT00001338 ↗ “a chemotherapy agent called cyclophosphamide (or Cytoxan) also at lower dose” NCT00595127 ↗ “Drug: Cyclophosphamide 750 mg/m2 i.v. for once (Day -5) Other Name: Cytoxan” NCT05211557 ↗ “Conditioning includes cytoxan 60mg/kg/d on Days 6 \& 5, total dose 120mg/kg” NCT00997529 ↗ “Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine” NCT00774332 ↗ “administering ZYC300 with Cyclophosphamide (Cytoxan).” NCT00381173 ↗ “Fluorouracil, Adriamycin, Cytoxan” NCT02995772 ↗ “Cyclophosphamide (CTX, Cytoxan)” NCT01861106 ↗ “Cyclophosphamide(CTX, Cytoxan)” NCT01176006 ↗ “Cyclophosphamide (Cytoxan)” NCT04339777 ↗ “cyclophosphamide (Cytoxan)” NCT00132691 ↗ “Cyclophosphamide, Cytoxan” NCT02981524 ↗ “Drug: Cytoxan” NCT00493649 ↗ “cytoxan” NCT00107276 ↗ |
| Known as | Cytoxan (Cyclophosphamide) | “Cytoxan (Cyclophosphamide)” NCT00636441 ↗ |
| Known as | Cytoxan(R) (cyclophosphamide) | “Cytoxan(R) (cyclophosphamide)” NCT00602667 ↗ |
| Known as | Dexamthasone | “Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)” NCT02203526 ↗ |
| Known as | Dual-Target Antigen-Selected CAR-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07410494 ↗ |
| Known as | Endoxan | “Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP)” NCT01352338 ↗11“Treatment by study drug Cyclophosphamide (Endoxan) in combination.” NCT05006664 ↗ “oral Cyclophosphamide (Endoxan®) 50mg/day” NCT00908869 ↗ “cyclophosphamide [Endoxan] 50 mg daily” NCT04604028 ↗ “Cyclophosphamide 600mg/m2 (endoxan)” NCT06531447 ↗ “Endoxan (Cyclophosphamide)” NCT02046915 ↗ |
| Known as | Endoxan(R), Cyclostin(R) = Cyclophosphamide | “Endoxan(R), Cyclostin(R) = Cyclophosphamide” NCT00991211 ↗ |
| Known as | Endoxana | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00523159 ↗ |
| Known as | Endoxana (Cyclophosphamide) | “Endoxana (Cyclophosphamide)” NCT00785122 ↗ |
| Known as | HD-Cy | “Conditioning chemotherapy included high-dose (3 g/m2) cyclophosphamide (HD-Cy) for 17 patients and low-dose (≤1.5 g/m2) cyclophosphamide (LD-Cy) for 8 patients.” PMID 31650176 ↗ Dec 2019 |
| Known as | IVC | “During the 24-week induction phase, patients were randomized to oral MMF (target dose 3.0 g/day) or intravenous cyclophosphamide (IVC) (0.5-1.0 g/m(2)/month), plus prednisone.” PMID 22922564 ↗ Aug 2012 |
| Known as | LD-Cy | “Conditioning chemotherapy included high-dose (3 g/m2) cyclophosphamide (HD-Cy) for 17 patients and low-dose (≤1.5 g/m2) cyclophosphamide (LD-Cy) for 8 patients.” PMID 31650176 ↗ Dec 2019 |
| Known as | mCTX | “metronomic cyclophosphamide (mCTX)” NCT01159288 ↗ |
| Known as | Metronomic Cyclophosphamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02117024 ↗ |
| Known as | NSC-26271 | “Iodine-131-labeled Monoclonal Antibody BC8 (anti-CD45), 131I-BC8; plus Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed by Allogeneic Bone Marrow, ABM; with,...” NCT00002554 ↗12“Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed by Allogeneic Bone Marrow, AlBM; with, as indicated, Intrathecal Cytarabine, IT ARA-C, NSC-63878.” NCT00002502 ↗ “Carboplatin, CBDCA, NSC-241240; or CAP: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Cisplatin, CDDP, NSC-119875.” NCT00002477 ↗ “CAF: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Fluorouracil, 5-FU, NSC-19893; followed by TMX.” NCT00929591 ↗ “CVP: Cyclophosphamide, CTX, NSC-26271; Etoposide, VP-16, NSC-141540; Cisplatin, CDDP, NSC-119875.” NCT00002488 ↗ “Anti-CD3 Murine Monoclonal Antibody OKT3, MOAB OKT3; with Cyclophosphamide, CTX, NSC-26271” NCT00002482 ↗ “Cyclophosphamide, CTX, NSC-26271” NCT00002471 ↗ “Cyclophosphamide, CTX, NSC-26271” NCT00002510 ↗ “CTX Cyclophosphamide, NSC-26271” NCT00002535 ↗ “CTX Cyclophosphamide, NSC-26271” NCT00002565 ↗ “CTX Cyclophosphamide, NSC-26271” NCT00002576 ↗ “CTX Cyclophosphamide, NSC-26271” NCT00002599 ↗ “CTX Cyclophosphamide, NSC-26271” NCT00002691 ↗ |
| Known as | NSC-3590 | “NSC-3590 CTX Cyclophosphamide” NCT00002704 ↗ |
| Known as | Post-Transplant Cyclophosphamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06001385 ↗ |
| Known as | Predisone | “Vindesin 4mg/d，Predisone:1mg/kg, d1-7, every month during maintenance treatment for 2 years” NCT02042690 ↗ |
| Known as | Preparative Regimen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01328496 ↗ |
| Known as | PT-CY | “This is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg/kg combined with...” NCT06705062 ↗15“Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease (GVHD)...” PMID 31481121 ↗ Sep 2019 “High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +90, and mycophenolate mofetil (MMF) on days +5 through...” NCT02579967 ↗ “We conducted a prospective randomized clinical trial to investigate the combination of posttransplant cyclophosphamide (PTCy) and abatacept (Aba) for graft-versus-host disease...” PMID 40554429 ↗ Aug 2025 “A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus...” NCT04202835 ↗ “This study evaluates the use of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) following allogeneic stem cell...” NCT06926595 ↗ “Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT)” NCT03983850 ↗ “Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT)” NCT05436418 ↗ “Post-transplant cyclophosphamide (PT-Cy) will be used in combination with MMF and tacrolimus (or cyclosporine) for standard GVHD prophylaxis.” NCT03842696 ↗ “We report a modified post-transplant cyclophosphamide (PT-CY) regimen, for unmanipulated haploidentical marrow transplants” PMID 29421292 ↗ Feb 2018 “Post-transplantation cyclophosphamide (PTCY) is considered as major graft versus host disease (GVHD) prophylaxis.” NCT06000982 ↗ “post-transplant cyclophosphamide (PTCy) has markedly reduced the incidence of both acute and chronic GVHD” NCT07570745 ↗ “Posttransplant cyclophosphamide (PTCy) is the main agent used for GVHD prevention in this setting.” PMID 37163349 ↗ Jul 2023 “post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis” PMID 38374026 ↗ Feb 2024 “low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3” NCT03395860 ↗ “Post-transplant Cyclophosphamide (PTCy)” NCT07214688 ↗ |
| Known as | Revimmune | “Revimmune” NCT02727803 ↗ |
| Known as | RJMty19 | “A Clinical Study for the Safety and Efficacy of CD19-CAR-DNT Cells (RJMty19) in the Treatment of Relapsed or Refractory Autoimmune Diseases” NCT06316076 ↗ |
| Known as | SC262 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06285422 ↗ |
| Known as | Sendoxan | “Cyclophosphamide, Sendoxan®, Baxter A/S” NCT00937300 ↗ |
| Known as | SN301A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06652243 ↗ |
| Known as | Syklofosfamid | “Syklofosfamid” NCT03918499 ↗ |
| Known as | Vepoliximab | “Vepoliximab: 1.8 mg/kg, Day 1” NCT07677813 ↗ |
| Known as | WR-138719 | “WR-138719” NCT03670966 ↗ |
| Known as | WTX221 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05800041 ↗ |
| Action | Inhibit | “Causes prevention of cell division by forming adducts with DNA” NCT00282412 ↗ |
| Modality | Other / unclassified | “An alkylating agent (cyclophosphamide or chlorambucil) combined with a corticosteroid regimen had short- and long-term benefits” PMID 34778952 ↗ Nov 2021 |
| Route | Intravenous | “Four medicines are given on day 1 of each cycle by vein (IV) (doxorubicin, cyclophosphamide, bleomycin, vincristine).” NCT00000689 ↗ |
| Target | CD19 | “express anti-CD19 CAR” NCT05453669 ↗ |